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Abstract: As treatment response for advanced renal cell carcinoma (RCC) is still limited, biomarkers to
diagnose and predict the applicability of drugs are needed. The deregulation of the Von HippelLindau
protein (pVHL)/hypoxiainducible factor (HIF) axis is a hallmark of clear cell RCC (ccRCC). Conse-
quently, protein products of HIFregulated genes are considered potential therapeutic targets of this
tumor type. In a previous work mass spectrometry analysis of RCC cell lines was used to define the
ccRCC protein surfaceome. The expression pattern of these proteins was further validated on mRNA
level. The overall objective of my PhD project was to select and analyse potential candidates of the
RCC surfaceome for clinical applications. We focused our interest on the mechanism of the aberrant and
frequent upregulation of CD70 in ccRCC. Since the discovery of the frequent overexpression of CD70
ccRCC in 2005, therapeutic antibodies targeting CD70 were developed, which are already under clin-
ical evaluation. However, studies elucidating the regulation of the CD70 expression in RCC and the
consequences of the constant interaction of CD70 with its unique receptor CD27 within the tumor mi-
croenvironment, are lacking. Immunohistochemical analyses of 667 RCC revealed elevated CD70 protein
expression in 80% of primary tumors and metastases of ccRCC and in 32% of papillary RCC. We have
found that in ccRCC abundant and frequent CD70 expression is directly driven by HIF. By analyz-
ing VHL mutations, mRNA and protein expression patterns of pVHL, HIF￿ and several HIF targets
in RCC tissues and cell lines, we found that CD70 upregulation is linked to the inactivation of pVHL.
Reexpression of pVHL in pVHLdeficient cell lines as well as silencing of HIF￿ lead to attenuated CD70
expression, whereas transient overexpression of HIF￿ and hypoxia lead to increased CD70. Gene promoter
analyses revealed that HIF directly binds to specific hypoxia response elements within the promoter of
CD70 thereby activating its transcription. Furthermore, CD27+ lymphocytes preferentially infiltrate
CD70expressing ccRCCs, which seems to be linked to a more aggressive biological behavior. Cocul-
turing of RCC cell lines with peripheral blood mononuclear cells induced significant increase of soluble
CD27 levels in the presence of CD70. This may explain the high soluble CD27 levels observed in the
sera of patients with CD70expressing ccRCC infiltrated by CD27+ lymphocytes, thus suggesting soluble
CD27 as diagnostic tool for ccRCC patient monitoring 2 Zusammenfassung Aufgrund des begrenzten Be-
handlungserfolgs von fortgeschrittenem Nierenzellkarzinom (NZK), bedarf es Biomarkern zur Diagnose
und Prognose der Anwendbarkeit von Medikamenten. Die Aufhebung der „Von Hippel‐Lindau‐Protein
(pVHL)/ Hypoxie‐ induzierbarer Faktor (HIF)“‐Achse ist ein Merkmal des klarzelligen NZK (kzNZK).
Daraus ergibt sich die Möglichkeit, dass Gene, die von HIF gesteuert werden als therapeutische Ziele
für diese Tumorart genutzt werden können. In einer früheren Arbeit wurde das Oberflächenproteom
des kzNZK durch eine massenspektrometrische Analyse definiert. Das Expressionsmuster dieser Proteine
wurde weiterhin auf mRNA‐Ebene validiert. Das Hauptanliegen meines PhD‐Projektes lag in der Auswahl
und Analyse potentieller Kandidaten des NZK‐Oberflächenproteoms für deren klinische Anwendbarkeit.
Wir richteten unser Interesse auf die Ursache der häufigen und fehlgeleiteten Überexpression von CD70 im
kzNZK. Seit der Entdeckung der hohen und häufigen CD70‐Expression im kzNZK im Jahre 2005 wurden
CD70‐zielgerichtete therapeutische Antikörper entwickelt, die schon klinisch getestet werden. Dennoch
gibt es keine Studien, die veranschaulichen, wodurch die kontinuierliche Hochregulierung von CD70 im
NZK gesteuert wird und was die Folgen der konstanten Interaktion von CD70 mit seinen einzig bekannten
Rezeptor CD27 für die nahe Umgebung des Tumors sind. Immunhistochemische Analysen von 667 NZK
ergaben eine erhöhte CD70‐ Expression in 80% der Primärtumoren und Metastasen des kzNZK und in
32% des papillären NZK. Wir haben herausgefunden, dass die hohe und häufige Expression von CD70 im
kzNZK direkt durch HIF angetrieben wird. Durch die Analyse der VHL‐Mutationen, der mRNA‐ und
Protein‐Expressionsmuster von pVHL, HIF￿ und verschiedener HIF‐gesteuerter Gene in NZK‐ Gewebe
und ‐Zelllinien, haben wir entdeckt, dass CD70 mit der Inaktivierung von pVHL verknüpft ist. Die
Wiederexpression von pVHL in pVHL‐defizienten Zelllinien als auch das Gen‐ Silencing von HIF￿ führten
zu einer Abschwächung der CD70‐Expression, wohingegen eine vorübergehende Überexpression von HIF￿
und Hypoxie CD70 erhöhten. Genepromoter‐ Analysen legten dar, dass HIF direkt an spezifische Hy-
poxie‐Antwort‐Elemente innerhalb des Promoters von CD70 bindet und dadurch dessen Transkription
auslöst. Des Weiteren infiltrieren CD27+ Lymphozyten bevorzugt CD70‐expreimierende kzNZK, was
mit einem vermehrt aggressiven biologischen Verhalten zusammenzuhängen scheint. Kokultivierung von
NZK‐Zelllinien mit mononukleären Zellen des periphären Blutes induzierten einen signifikanten Anstieg
der gelösten CD27‐Menge an Anwesenheit von CD70. Dies könnte die Ursache der erhöhten gelösten
CD27‐Mengen im Blutserum von Patienten mit CD70‐ exprimierenden NZK, die von CD27+ Lym-
phozyten infiltriert sind, sein. Deshalb ist der Einsatz von gelöstem CD27 als diagnostisches Instrument
für die kzNZK‐Patientenbeobachtung denkbar.
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2‐OG  2‐oxoglutarate  FH fumarate hydratase
3p  shorter arm of chromosome 3  fi functional impact
5'azaC  5‐azacytidine   FLCN gene encoding folliculin 
AKT  gene encoding protein kinase B  FNIP protein binding to folliculin 
ALCAM  activated leukocyte cell adhesion molecule GFP  green fluorescent protein 
AMPK  5' adenosine monophosphate‐activated protein kinase Glut‐1 glucose transporter 1 
APC  antigen‐presenting cell  HA influenza hemagglutinin 
AQUA  automated quantitative analysis  HAF hypoxia‐associated factor 
Asn  Asparagine  HCl hydrogen chloride
ATCC  American type culture collection  HEK human embryonic kidney 
BATF  basic leucine zipper transcription factor, ATF‐like HGF‐R hepatocyte growth factor receptor 
BHD  Birt‐Hogg‐Dubé  HIF hypoxia‐inducible factor 
bHLH  basic helix‐loop‐helix domain   HRE hypoxia response element 
bp  base pairs  HRP horseradish peroxidase 
BSA  bovine serum albumin  hypo hypoxia
CA‐IX  carbonic anhydrase 9  IFN interferon
cc‐pap  clear cell papillary IGF2R insulin‐like growth factor 2 receptor 
ccRCC  clear cell renal cell carcinoma  IHC immunohistochemistry 
CD  cluster of differentiation  IL interleukin




cDNA  complementary DNA  KCNJ5 G protein‐activated inward rectifier potassium 
channel 4 
ChIP  chromatin immuno precipitation  kDa kilo dalton
chromo  Chromophobe  Ki‐67 antigen KI‐67
c‐Jun  transcription factor KLRG1 Killer cell lectin‐like receptor subfamily G member 
1 
CpG  cytosine‐phosphate‐guanine   kzNZK klarzelliges NZK
CRP  C‐reactive protein LB lysogeny broth
CT  computer scanning LKB serine/threonine kinase 
Cul2  Cullin‐2  lof loss of function
DAPI  4’,6‐diamidino‐2‐phenylindole   MET gene encoding hepatocyte growth factor receptor
DMEM  Dulbecco’s modified Eagle's medium  met metastatic
DNA  deoxyribonucleic acid  miR microRNA
DTT  dithiothreitol   MOPS 3‐(N‐morpholino)propansulfonic acid 
E. coli  Escherichia coli  mRNA messenger RNA
E3  ubiquitin ligase  ms missense
ECL  Enhanced chemiluminescence  mTOR mammalian target of rapamycin 
EDTA  ethylenediaminetetraacetic acid  MTORC mTOR complex
EGFR  epidermal growth factor receptor  MTT tetrazolium dye
ELISA  enzyme‐linked immunosorbent assay  mut mutated
EPAS  gene encoding HIF2α  MYC regulator gene




NK  natural killer  SDM site director mutator
NRC‐1  non‐papillary renal carcinoma 1  SDS sodium dodecyl sulfate 
N‐TAD  amino terminal TAD SEER Surveillance, Epidemiology, and End Results 
Program 
NZK  Nierenzellkarzinom Ser serine
OCT4  gene encoding octamer‐binding transcription factor 4 siRNA silencer RNA
OD  optical density  siScr siScramble
ODD  oxygen‐dependent degradation domain Siva1 apoptosis regulatory protein 
OH  hydroxyl group  SNG‐75 CD70 targeting drug‐conjugated antibody 
P2P  PHD2 promoter construct   SRM small renal mass
p53  tumor protein p53 TAD transactivation domain 
pap  Papillary  TAE Tris base, acetic acid and EDTA. 
PAS  PER‐ARNT‐SIM  T‐BET T‐box transcription factor TBX21 
PBMC  peripheral blood mononuclear cells  TBS‐T Tris‐buffered saline containing Tween  
PBRM1  gene encoding protein polybromo‐1  TCEB1 gene encoding elongin C 
PBS  phosphate buffered saline  TCEP tris(2‐carboxyethyl)phosphine  
PCR  polymerase chain reaction  TCR T cell receptor
PD1  programmed cell death protein 1  TFB transforming buffer
PDGF  platelet derived growth factor  TGF‐βRIII transforming growth factor beta receptor 3




PD‐L1  programmed death‐ligand 1  TLR toll‐like receptor
PHD  prolyl hydroxylase TMA tissue microarray
PI3K  phosphatidylinositol‐4,5‐bisphosphate 3‐kinase TNF tumor necrosis factor 
PKB  protein kinase B  TNM tumor, lymphnode and metastasis 
pM  pathologic examination of a metastasis  TP53 gene encoding tumor protein p53 
pN  pathologic examination of a lymph node TRACK transgenic model of cancer of the kidney 
postOP  after surgery  TRAF TNF receptor‐associated factor 
PPIA  peptidylprolyl isomerase A  TSC tuberous sclerosis complex 
Pro  Proline  ub ubiquitin
pT  pathologic examination of a tumor  US United States
PTEN  gene encoding phosphatase and tensin homolog VEGF vascular endothelial growth factor 
PTPRJ  protein tyrosine phosphatase receptor J VEGFR VEGF receptor
pVHL  Von Hippel‐Lindau protein  VHL Von Hippel‐Lindau gene 





















diagnose  and  predict  the  applicability  of  drugs  are  needed.  The  deregulation  of  the  Von 
Hippel‐Lindau protein (pVHL)/hypoxia‐inducible factor (HIF) axis is a hallmark of clear cell RCC 







antibodies  targeting  CD70  were  developed,  which  are  already  under  clinical  evaluation. 
However,  studies  elucidating  the  regulation  of  the  CD70  expression  in  RCC  and  the 
consequences of the constant interaction of CD70 with its unique receptor CD27 within the 




of  pVHL, HIFα  and  several HIF  targets  in  RCC  tissues  and  cell  lines, we  found  that  CD70 
upregulation is linked to the inactivation of pVHL. Reexpression of pVHL in pVHL‐deficient cell 












Aufgrund  des  begrenzten  Behandlungserfolgs  von  fortgeschrittenem  Nierenzellkarzinom 
(NZK),  bedarf  es  Biomarkern  zur  Diagnose  und  Prognose  der  Anwendbarkeit  von 
Medikamenten.  Die  Aufhebung  der  „Von  Hippel‐Lindau‐Protein  (pVHL)/  Hypoxie‐
induzierbarer Faktor (HIF)“‐Achse ist ein Merkmal des klarzelligen NZK (kzNZK). Daraus ergibt 
sich die Möglichkeit, dass Gene, die von HIF gesteuert werden als  therapeutische Ziele  für 
diese  Tumorart  genutzt  werden  können.  In  einer  früheren  Arbeit  wurde  das 
Oberflächenproteom des kzNZK durch eine massenspektrometrische Analyse definiert. Das 
Expressionsmuster  dieser  Proteine  wurde  weiterhin  auf  mRNA‐Ebene  validiert.  Das 
Hauptanliegen meines PhD‐Projektes lag in der Auswahl und Analyse potentieller Kandidaten 




Dennoch  gibt  es  keine  Studien,  die  veranschaulichen,  wodurch  die  kontinuierliche 
Hochregulierung  von  CD70  im  NZK  gesteuert  wird  und  was  die  Folgen  der  konstanten 
Interaktion von CD70 mit seinen einzig bekannten Rezeptor CD27 für die nahe Umgebung des 





Gewebe  und  ‐Zelllinien,  haben wir  entdeckt,  dass  CD70 mit  der  Inaktivierung  von  pVHL 
verknüpft ist. Die Wiederexpression von pVHL in pVHL‐defizienten Zelllinien als auch das Gen‐
Silencing von HIFα  führten zu einer Abschwächung der CD70‐Expression, wohingegen eine 
vorübergehende  Überexpression  von  HIFα  und  Hypoxie  CD70  erhöhten.  Genepromoter‐
Analysen legten dar, dass HIF direkt an spezifische Hypoxie‐Antwort‐Elemente innerhalb des 
Promoters  von  CD70  bindet  und  dadurch  dessen  Transkription  auslöst.  Des  Weiteren 
infiltrieren  CD27+  Lymphozyten  bevorzugt  CD70‐expreimierende  kzNZK,  was  mit  einem 
vermehrt aggressiven biologischen Verhalten zusammenzuhängen scheint. Kokultivierung von 




Ursache  der  erhöhten  gelösten  CD27‐Mengen  im  Blutserum  von  Patienten  mit  CD70‐
exprimierenden NZK, die von CD27+ Lymphozyten infiltriert sind, sein. Deshalb ist der Einsatz 










































































































































The  VHL  protein  is  a  component  of  oxygen  and  iron  sensing  pathway  that  regulates  the 
hypoxia‐inducible factor (HIF) [21]. Two key pathways are essential to the pathophysiology of 






TSC2  (tuberous  sclerosis  complex  1  and  2),  FLCN  (or  BHD:  folliculin),  FH  (fumarate  hydratase),  SDH 













type  [31].  Hepatocyte  growth  factor  (HGF)‐MET  signalling  affects  the  LKB1‐AMTK  energy 











The  number  of  incidentally  diagnosed  RCCs  have  risen  because  of  improved  imaging 
techniques  [3].  CT  scanning  remains  the  standard  test  for  diagnosis.  Eighty  to  eighty‐five 
percent  of  small  renal masses  (SRM)  of more  than  4  cm  are  RCCs  per  definition  [36].  In 
addition, biopsies have gained diagnostic accuracy of more than 80%  [37]. Together, these 
advanced diagnostic  tools made  it possible  that more  low‐grade RCCs with  low malignant 
potential are being found [3].  
In RCC many parameters have been tested for prognostic significance, but only a few achieved 





















































10%  until  targeted  therapies were  introduced  [50].  These  therapies  affect mTOR  or  the 
downstream  targets of pVHL pathway  (VEGF, VEGFR, PDGFR). Bevacicumab  is an antibody 
targeting VEGF, whereas sunitinib, sorafenib and axitinib are small‐molecule receptor tyrosine 
kinase  inhibitors  targeting  VEGFR  and  PDGFR.  Small‐molecules  inhibiting  mTOR  are 










mutations or by hypermethylation of  the  remaining allele  in heterozygous cases  [26]. This 
indicates that this tumor suppressor gene is centrally involved in the development of ccRCC 
[25]. pVHL acts as an adaptor protein  to  recruit effector proteins  to  their  target proteins. 
Thereby it regulates HIFα for its proteolytic degradation [54], microtubule stability [55], the 
maintenance of the primary cilium [56], the activation of p53 [57], neuronal apoptosis [58], 
epithelial‐mesenchymal  transition  [59],  cellular  senescence  [60]  and  aneuploidy  [61], 
secretion of extracellular components [62], growth factor receptor internalization [63], WNT 
signaling  [64],  ubiquitination  of  RNA  polymerase  II  [65],  degradation  of  β2‐adrenergic 
receptors  [66] and activity of nuclear  factor  (NF)‐κB  [67]. Deregulation of  these processes 
leads to tumorigenesis and tumor progression [25]. It was shown that pVHL‐deficiency alone 
is not  sufficient  to  initiate  tumor  formation  [68],  therefore  it  is  speculated  that additional 
affected  genes must  be  included.  Genomic  scale  technologies  elucidated  that  there  are 





and Cul2,  that  targets HIF1  and  2α  for  oxygen‐dependent,  ubiquitin‐mediated  proteolytic 


































prolyl‐hydroxylases  (PHDs) modify  the HIFα‐subunits, so  that  they can be degraded by  the 
proteasome, mediated by pVHL [76]. Because the function of pVHL is lost in 92% of ccRCCs, 
prolyl‐hydroxylated  HIFα  subunits  cannot  be  bound  by  pVHL  and  targeted  for  ubiquitin‐
mediated proteolysis [78]. Increased expression of HIFα proteins in tumor cells actively drives 
tumor  growth  and  progression  by  regulating  the  expression  of  crucial  target  genes.  The 
Introduction 
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transcriptional  specificity  resides  in  the amino‐terminal  transactivation domain  (N‐TAD) of 









of  anabolic metabolism  [25,  81].  HIF  activates  the  expression  of  glycolytic  enzymes  and 
glucose transporters. By the deprivation of pyruvate through the overexpression of pyruvate 
dehydrogenase kinase 1 and lactate dehydrogenase A, HIF mediates a Warburg‐like metabolic 
shift  in  ccRCC  [82]. HIF  inhibits MYC  thereby  reducing mitochondrial  respiration  [83].  The 
increased pentose‐phosphate pathway provides  the  tumor  cell with NADPH  and  ribose‐5‐
phosphate [84]. 
4.3 Biomarkers for RCC 





























One of  the  candidates, CD70,  a member of  the  tumor necrosis  factor  ligand  superfamily, 







linked  glycosylation  sites  with  a  molecular  mass  of  50  kDa  [105,  106]  (Fig  6A).  The 
homotrimeric type II membrane protein has been shown to exist only in the membrane‐bound 































The  interaction of CD70 with  its  receptor CD27 promotes expansion and differentiation of 
memory and effector T cells as well as B cell expansion and plasma cell differentiation [104, 
























Non‐Hodgkin’s lymphoma       
Diffuse large B cell lymphoma  71%  Clear cell renal cell carcinoma [125]  65% (59/91) 
High grade B lymphoma  58%  Papillary renal cell carcinoma [125]  40% (9/23) 
Follicular lymphoma  33%  Glioblastoma [127]  not quantifiable 
Mantle cell lymphoma  25%  Astrocytoma [127]  not quantifiable 
Chronic lymphocytic leukemia  50%  Nasopharyngeal carcinoma [128]  80% (16/20) 




Interestingly,  CD70  expression  is  less  prevalent  in VHL  non‐related  RCC  subtypes.  Studies 
elucidating the consequences of the constitutive expression of CD70 and its interaction with 
CD27  in  ccRCC are  rare and  controversial. While  some authors hypothesized  that CD70  is 
involved  in  an  immune escape mechanism of RCC by mediating apoptosis  in  lymphocytes 
[129], others suggested that CD70 rather triggers a phenotypic conversion of CD27+ tumor 




The  constitutive  expression  of  CD70  in multiple  solid  tumors  paired  with  the  restricted 
expression  on normal  cells makes CD70  an  attractive  target  for  antibody‐based  therapies 
without undesirable effects on non‐CD70 expressing cells. Antibodies, that can deplete CD70‐





been  demonstrated  with  CD70‐expressing  lymphoma,  multiple  myeloma,  glioblastoma, 













Since  the high and unique  frequency of CD70 overexpression  in ccRCC  resembles  the VHL 
mutation frequency being characteristic for this subtype, it might be conceivable that those 
two alterations of ccRCC could be connected with each other. Until now the  impact of the 











subdivided  into  three  chapters. We  focused our  interest mainly on  the mechanism of  the 




























Gene expression analysis of 116 RCC  tissues  [145]  revealed  that CD70 was upregulated  in 
primary and metastatic ccRCC (Fig. 7A). Using tissue micro arrays (TMAs) containing a total of 
667 RCCs, we observed strong membranous CD70 protein expression in 78% of ccRCCs, but in 
only  32%  of  papillary  RCC.  Oncocytomas,  chromophobe  RCCs  and  normal  kidneys  were 
negative  (Fig.  7B,  C).  Furthermore,  54  ccRCC  brain  metastases  showed  a  similar  CD70 
expression  frequency as observed  in primary  tumors. Notably,  the strong CD70 expression 
seen  in  nine  primary  ccRCCs  remained  constant  in  their  corresponding  brain metastasis 
(Fig.  7D). Other  primary  solid  tumors,  as  breast  and  lung  cancer  did  not  show  any  CD70 





























immunostained  ccRCCs  and  papillary  RCCs  (40x  magnification, 
bars:  20  µm).  C)  Histogram  representing  CD70  expression 
intensities  in RCC and normal kidney  tissue. Pearson  χ2  tests or 
Fisher's exact test were performed. D) Representative pictures of 
anti‐CD70‐immunostained  localized  ccRCC  and  corresponding 
brain metastasis  (n=8,  20x magnification,  bars:  50  µm).  T  tests 
were  performed.  E)  CD70‐immunostained  primary  tumors  of 
kidney, lung or breast. pap: papillary, chromo: chromophobe, met: 













CD70 antibody, we knocked down CD70  in both A498 and 786‐O  cells with  four different 





A)  Western  blot  of  CD70  in  786‐O  and  B)  A498  treated  with  siRNA  targeting  CD70 
(siCD70#1‐4) or treated with siRNA control (siScr) for 48 hours (h).  
 
The  NetNGlyc  1.0  server  predicts  two  N‐glycosylation  sites  within  the  193  amino  acid 
sequence of CD70 by using artificial neural networks that examine the sequence context of 





deglycosylation  represent  the dimeric and  trimeric  forms of CD70. The oligomers are held 
together by disulfide bonds [105], which might be too strong to be broken by the reducing 
conditions of the Western blot run. Additional pretreatment of the cell lysates with the strong 
reducing agent  tris(2‐carboxyethyl)phosphine  (TCEP) changed  the banding pattern of CD70 
only slightly  in the Western blot (Fig. 10D). Thus, the TCEP‐treatment did either not reduce 
the disulfide bonds completely or the bands arise from another origin. Fluorescent staining of 















Figure 11. CD70  is  localized  in  the  cytoplasm and  the  cell 
membrane.  
Fluorescent  staining  of  CD70  and  4’,6‐diamidino‐2‐












can  impair  the pVHL protein  function, we used  the  software Site Director mutator  (SDM), 
which predicts  the effect of a missense mutation on  the protein stability  [151, 152]. CD70 
expression was more frequent in tumors with VHL mutations, which predict impaired function 












To  confirm  these  findings  in  vitro, we  sequenced  the  VHL  gene  in  17  RCC  cell  lines  and 







or were positive  for at  least one of  them. CD70 was  found  to be upregulated more often 
HIF2α‐expressing cell lines, since many of the VHL‐mutated RCC cell lines have homozygous 













HK2  proximal tubule   wt     ‐  ‐    ‐ 
HEK293  embryonic  wt     ‐  ‐    ‐ 
SLR21  clear cell carcinoma  wt     ‐  ‐    diploid 
ACHN  adenocarcinoma   wt     ‐  ‐    ‐ 
Caki‐1  clear cell carcinoma  wt     ‐  ‐    ‐ 

















































































analyses  (Fig.  13C)  of  pVHL‐deficient  RCC  cell  lines  786‐O  and  A498  and  their  stable 
transfectants reexpressing pVHL. Reconstituted pVHL lead to a decrease of CD70 expression 
and the HIF targets CA‐IX, GLUT1, OCT4 and PHD3. TMA analyses demonstrated a significant 
association  of  CD70  expression  and  pVHL/HIF  deregulation.  CD70  expression was  directly 
correlated with the expression of HIF1α (p=0.0136, Pearson R=0.1359) and HIF2α (p<0.0001, 
Pearson R=0.2833) as well as with the expression of the HIF targets CA‐IX (p<0.0001, Pearson 

















































We  performed  ChIP  with  HIF2α‐,  HIF1α‐  and  corresponding  isotype  control‐antibodies 
(Fig. 16A, B) to elucidate if CD70 represents a potential HIF target. We investigated HIF’s ability 
to  bind  to  the  eight  potential HREs  residing  in  2.7  kb  of  the  putative  promoter  of  CD70 
(Fig. 16C). The reconstitution of pVHL  in 786‐O, A498 and RCC4  leads to a reduction of the 
direct binding of HIF2α and HIF1α to HRE3, 4 and 8  in the CD70 promoter. No binding was 









A) Binding of HIF2 and B) HIF1 at  the CD70 promoter  relative  to  its  isotype  controls analyzed by ChIP. C) Schematic 







D). By  subdividing  the CD70 promoter  into  fragments containing  the different HRE  islands 
(Fig.  17E)  we  found,  that  the  binding  of  HIF  to  HREs  4‐7  and  8  indeed  induced  the 
transcriptional activity, whereas the binding to HREs 1‐3 did not (Fig. 17F, G). These results 





















cell  lines with  increasing CD70 expression  levels and  the epithelial kidney cell  line HK‐2 as 
negative control. Interestingly, there was a weak association of hypomethylation of CpGs to 
overexpression  of  CD70  in  ccRCC  cell  lines  (Fig.  18A).  However,  the  inhibition  of  DNA 




























the Western  blot  using  four  different  siRNAs  and  iii)  CD27  mRNA  levels  from  the  gene 











6.1.8 CD27+  lymphocytes preferentially  infiltrate CD70‐expressing tumors which correlates 
with worse patient outcome 
 




memory  cells  than  the  peripheral  blood mononuclear  lymphocytes  (PBMCs)  of  the  same 
patient. Furthermore, they suggested that this phenotypic conversion of the T cells is caused 
by high CD70 tumor expression. Our qPCR analysis of 47 ccRCCs selected from the TMA, which 













CD27  and  CD70  gene  expression  obtained  from  a  recent  DNA‐microarray  analysis  [145] 
confirmed this finding (Fig. 20B). The strong correlation between CD27 and the subunits of the 
T cell marker CD3  indicated  that  the CD27 stained  lymphocytes were T cells  (Fig. 14C). To 
validate the gene expression data on protein level, we investigated CD70 and CD27 expression 
patterns  on  large  consecutive  tissue  sections  of  41  ccRCC  infiltrated  by  lymphocytes. We 













Fuhrman low grade (1‐2)  9 (10.8)  7 (77.8)   p<0.0001 
  Fuhrman high grade (3‐4)  74( 89.2)  2 (22.2) 





























in  collaboration with  the  department  of Urology, University Hospital  Zurich  (Table  7).  To 












































lymphoma  [156, 157]. Therefore we  tested  if  the  interaction of CD27 present on TILs with 













apoptosis  in  coculture  experiments  [129,  149,  158].  However,  the  immune  inhibitory 























correlates with  CD27  in  ccRCC  (p=0.0003;  see  fig.  20B).  This means  that CD70‐expressing 
ccRCCs harbor more exhausted CD27+ T cells than CD70‐negative ccRCCs in total, but not that 
CD27+ T cells are more exhausted in CD70‐expressing ccRCCs than in CD70‐negative ccRCCs.  
To test  if CD70  leads to a conversion of T cells to a more exhausted phenotype  in vitro we 
cocultured IL2‐activated PBMCs with CD70‐postive and ‐negative RCC cell lines as before (see 










Neither  from  the  INFγ  release  data  nor  from  the  expression  of  T  cell  exhaustion  and 
senescence  markers  we  can  conclude  that  CD70  on  RCC  cells  provokes  a  phenotypic 
conversion of PBMCs to a more exhausted state in vitro within the time analyzed (Fig. 20A, B). 
After  coculture  with  activated  PBMCs  for  48  hours  no  RCC  cells  were  left,  making  the 
assessment of putative changes in the migration behavior of CD70‐positive and CD70‐negative 
RCC cell in response to the interaction with lymphocytes impossible.  
However,  our  gene  expression  analysis  of  exhaustion  markers  in  vivo  accords  with  the 






A previous PhD  thesis project  focused on one of  the biomarker candidates  termed PTPRJ, 
which was reduced in ccRCC as a consequence of pVHL loss [103]. To validate the findings of 
PTPRJ’s  role  in  RCC,  additional  experiments were  needed  to  publish  the  study.  First, we 
validated  reduced  levels of PTPRJ protein  in  tumor  tissues. By using additional  siRNAs we 
confirmed an experiment showing that PTPRJ mRNA is increased to its basic level when HIF2α 






6.3 The  tumor  progression  suppressor  TGF‐βRIII  increases  with  tumor 
progression in the sera of RCC patients 
In addition to CD70, the presence of six other promising biomarker candidates, which were 






Figure  27.  TGF‐βRIII  rises  with  tumor 
progression in the serum of RCC patients.  
A) Analyzed biomarker candidates. B) TGF‐βRIII 
serum  concentrations  of  RCC  patients 
separated according  to  tumor  stage  (pT). **, 
p<0.005; *  , p<0.05 by  t  test. C) CD70  serum 




The  first candidate,  transforming growth  factor beta receptor 3, TGF‐βRIII, a suppressor of 
cancer progression was shown to be reduced in RCC as well as in multiple cancers [164]. Low 
density array‐ and genechip‐based experiments revealed a generally lower expression in RCC 























the  sera of patients with CD70‐expressing  tumors  suggest  that  sCD27  is a putative  serum 
marker for CD70‐positive ccRCC patients (Fig. 28). 






RCCs  showed  abnormal  CD70  expression  in  78%  of  ccRCCs,  which  was  consistent  with 
previously  described  frequencies  [124,  125].  Our  comprehensive  CD70  analysis  of  348 





















We  show  that  the  abnormal  upregulation  of  CD70  in  ccRCC  is  closely  related  to  the 
deregulation of the pVHL/HIF axis. CD70 expression patterns in ccRCC tissue were significantly 
correlated with  those  seen  for HIF and  the HIF  targets CA‐IX, Glut1 and CD10  [103]. The 
analysis of the mutation status of VHL in 363 ccRCCs and 17 RCC cell lines further supported 
the  association  of CD70  expression with VHL  sequence  alterations. High CD70  expression 
levels were significantly  linked to VHL mutations that very  likely abrogate pVHL’s  function. 
Inactivation of VHL by hypermethylation of its promoter [166] and missense mutations with 





resemble  those  20%  (34/174)  of  CD70‐negative  ccRCCs,  which  had  VHL  mutations  with 
functional impact on pVHL, presumably causing HIFα stabilization. Epigenetic modification of 












N‐terminal  53  amino  acids  (pVHL19)  does  not. Although  both  pVHL30  and  pVHL19  act  as  a 
substrate  recognition  subunit  in  the  E3  ubiquitin  ligase  complex,  interaction  partners  of 































in  several  T  cell  affecting  diseases,  such  as  systemic  lupus  erythematosus  and  systemic 
sclerosis  [141, 172]  in which hypomethylation of  the CD70 promoter  contributes  to CD70 
overexpression. Using the same methylation‐specific PCR protocol described by Yu et al. [142] 





before  [126,  149].  CD70  is  a  homotrimer  [105,  107].  Protter  predicts  that  they  are  held 
together by disulfide bonds [122]. Moreover we could show that some of these bands are N‐
glycosylated  forms of CD70, as predicted by  the NetNGlyc server  [150]. We observed  that 
CD70 is glycosylated in a different way in RCC cells than in lymphpoma cell line Raji. Since the 
banding  pattern  in  RCC  cells  is  the  same  as  in  the  embryonic  kidney  cell  line  HEK293 
transfected  with  CD70  [134],  we  concluded  that  the  organ  expressing  CD70  probably 












by  renal  ischemia‐reperfusion  injury  [154]. This plays most  likely a negligible  role  for RCC, 
because we only found very weak expression of CD27 in rare cases in the tumor cells of RCC. 
However,  microarray  gene  expression  data  of  ccRCC  revealed  a  significant  correlation 
between CD70 and CD27 expression. A detailed  IHC analysis of  large ccRCC tissue sections 
demonstrated  that  the  lymphocyte  infiltrates  in CD70‐expressing  tumors contained almost 
always CD27+ lymphocytes. Since CD27 highly correlated with T cell marker CD3 subunits (ε, γ 





tumor  grade,  stage  and  patient  survival  in  ccRCC  [125,  126].  In  contrast,  high  CD70 was 
associated  with  a  worse  overall  survival  outcome  in  diffuse  large  B  cell  lymphoma  and 
advanced ovarian carcinomas in previous reports [173, 174]. As the loss of pVHL function is 












Different  tumor‐promoting mechanisms have been proposed  in  this context. Soluble CD27 
was  able  to  induce proliferation  in CD70‐positive  acute  lymphoblastic  leukemia  and nasal 
NK/T cell  lymphoma [156, 157]. Adding sCD27 to stimulated PBMCs was shown to  increase 
T  cell  activation  and  proliferation  [175].  T  cells  proliferation  was  enhanced  in  a  dose‐
dependent manner with increasing amounts of recombinant sCD27 when they were treated 
additionally with a TCR‐stimulus (anti‐CD3/CD28 and IL‐2) [175]. It was therefore tempting to 
speculate  that  the  interaction of CD27+ TILs with CD70 present on  ccRCC  cells  could have 
similar effects and accelerate tumor cell growth. However, we could not see any proliferative 








[159].  In vivo CD27 promotes survival of activated T cells  throughout successive  rounds of 
division  and  thereby  contributes  to  the  accumulation  of  effector  T  cells  [176].  For  these 
reasons and because we do  see many CD27+ T  cells  in  situ, we presume  that  the  chronic 
CD70/CD27  interaction within  ccRCCs  rather  promotes  T  cell  activation  instead  of  T  cell 
apoptosis in vivo.  
7.2.5 Continuous T cell activation leads to T cell exhaustion 
The  continuous  ligation  of  CD27  and  CD70 may  also  lead  to  T  cell  exhaustion,  a  kind  of 
























T  cell  exhaustion  does  not  significantly  correlate  with  CD70.  The  punches  used  for  the 
geneChip microarray might therefore not represent the situation of the whole tumor.  
Claus and colleagues [131] studied the CD70/CD27 interaction in the immunologic control of 
different  CD70‐negative  solid  tumors  in  CD27‐deficient mice.  They  found  that  in  tumor‐
bearing wild‐type mice,  the  CD27  signaling  increased  the  frequency  of  regulatory  T  cells, 
reduced tumor‐specific T‐cell responses, increased angiogenesis and promoted tumor growth. 
Other research groups proposed that CD70/CD27  interaction  improves antitumor  immunity 
[159, 178]. For example,  injection of a CD27‐activating antibody  improved  tumor rejection 
[178]  and  B  cell‐  and  dendritic  cell‐specific  CD70‐transgenic mice were  protected  against 
poorly  immunogenic  tumor cells  [177, 179]. Two  reviews concluded  that  the duration and 
dosing of CD70 expression may be decisive weather CD70/CD27 interaction leads to adaptive 
immune response or  immunopathology  (Fig. 29)  [117, 180].  In  the context of  the previous 
findings by Wang et al. [130] our results supports the presumption that the coexistence of 




of both CD70 and CD27 within ccRCC, we presume  that  the persistent CD70 expression  in 
primary tumors and metastatic sites of ccRCC causes immunopathology.  
 
Figure  29.  The  strength  of  costimulatory  signals 
determines the outcome of immune reactions.  
Adapted from Nolte et al., 2009 [117]. Low‐level triggering 
(as  in  deficient  mice  or  after  treatment  with  blocking 
antibodies) diminishes  immune responses (left‐hand side 
of  the  figure), whereas continuous and strong activation 
limits  immune  reactivity  and  leads  via  chronic  immune 
activation  to  the  collapse  of  the  immune  system  (right‐







dependent  increase of sCD27  in the supernatant  in our study. A similar effect may occur  in 








CD4+  T  cells  are  its  predominant  source.  They  observed  that  the  production  of  sCD27 
correlated  linearly with the amount of CD70‐expressing CD8+ T cells within the culture and 











emerge  from metastasized tumors or  from tumor‐independent  immune activation. Soluble 



















papillary RCC, however, mRNA  and protein  levels of PTPRJ were  retained  to  the  levels of 



















its surface expression  is  lower  in ccRCC and papillary RCC than  in normal kidney. However, 
higher expression in pVHL‐deficient ccRCCs than in ccRCCs with intact pVHL function was also 









βRIII serum  levels.  It might be possible,  that soluble TGF‐βRIII acts also  in ccRCC  in tumor‐














We confirmed  that  the converse expression of  the  two proteins CD70 and PTPRJ  in ccRCC 




An  additional promising  serum marker  for  ccRCC progression  is  TGF‐βRIII,  since  its  serum 
levels correlated with the tumor stage.  
In conclusion, the large amounts of data generated by high‐throughput technologies such as 




















the  Institute  of  Surgical  Pathology, University Hospital  of  Zurich,  Switzerland,  and  a  TMA 
comprising 300 papillary RCCs  [146]  from the University of Erlangen, Germany, were used. 
Each  TMA  was  histologically  reviewed  by  one  pathologist  (H.M.  and  A.H.,  respectively) 
(Table 6). Clinico‐pathological parameters of  the TMAs have already been described  [146, 
201]. This study was approved by  the  local ethics commission  (reference no. StV38‐2005). 
Human blood samples of 20 ml of 74 patients, who underwent full or partial nephrectomy as 
part of their standard treatment at the Department of Urology, University Hospital Zurich  , 





Formalin‐fixed, paraffin‐embedded  tissue samples  from  these patients were also available. 
Sera and plasma of 17 healthy persons, with prior informed consent, served as control. Serum 
























54  RCC brain metastasis Institute  of  Surgical  Pathology,  University 
Hospital of Zurich, Switzerland 9  benign brain tumor 
solid tumor  24  ccRCC, of which 13 match to the brain metastasis TMA Institute  of  Surgical  Pathology,  University 
Hospital of Zurich, Switzerland 112  pulmonary carcinoma
20  mammary carcinoma
RCC cell line  23  cell lines derived from RCC or kidney Institute  of  Surgical  Pathology,  University 
Hospital of Zurich, Switzerland 





number of tumors  Fuhrman grade  tumor stage (pT) follow up samples (months after surgery)  met.




33 ccRCCs  3  18  8  3  11 10 1 8 20 12 17 9  11  2
1 ccRCC + chromophobe    1      1    
3 ccRCC/ papRCC    2  1    2 2 2 1     1 died
8 chromophobe RCC  2  3      3 2 1 4 1 6 4  2 
11 papillary RCC  3  4  3  1  8 2 1 9 3 5 7  1 
1 pap./chromo. RCC          1 1 1    
3 oncocytoma          1 1   
11 benign tumors          5 1 2    
2 not classified    1  1    1 1 1 1 2 1  1 
1 perivascular 
epithelioid cell tumor 

















CD70  MAB2738  1:500  1:75  ‐  R&D systems 
CD70  Ki‐24  ‐  ‐  ‐  10 μg/ml PharMingen 
CD27  ab70103  1:1000  1:200  ‐  Abcam 
HIF1  NB100‐479  1:500  ‐  ‐  Novus Biologicals 
HIF1  ab16066  ‐  1:400  ‐  Abcam 
HIF1  NB100‐105  ‐  ‐  10 μg  Novus Biologicals 
HIF2  PAB12124  1:500  ‐  ‐  Abnova 
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HIF2  NB100‐122  ‐  1:150  10 ug  Novus Biologicals 
CA‐IX  M75  1:1000  1:200  ‐  J.  Zavada,  Prague,  Czech Republic 
Glut1  AB1341  ‐  1:1000  ‐  Chemicon 
Glut1  07‐1401  1:1000  ‐  ‐  Millipore 
pVHL    1:500  1:50  ‐  W. Krek, ETH Zurich 
CD10  NCL‐CD10‐270  ‐  1:30  ‐  Novocastra Laboratories 
E‐Cadherin  ECH‐6  ‐  1:10  ‐  Cell Marque 
β‐actin  MAB1501  1:2000  ‐  ‐  Millipore 
IgG2b  MAB004  ‐  ‐  10 ug  R and D systems  
Rabbit IgG  NB810‐56910  ‐  ‐  10 ug  Novus Biologicals 
HRP‐conjugated 
anti‐mouse  ab672  1:2000  ‐  ‐  Abcam 
HRP‐conjugated 
anti‐rabbit  7074  1:1000  ‐  ‐  Cell signaling 
9.3 VHL mutation analysis 
VHL mutation analysis of cell lines and tissues was performed as described [151] with primers 
listed  in  table  9. Cell  line VHL mutations  are  listed  in  table  4.  The  program  Site Directed 


















The RCC‐derived  cell  lines ACHN, A704, Caki‐1, Caki‐2, KC12, 769P, 786‐O and  the human 
kidney cell lines HK‐2 and HEK‐293 were supplied by American Type Culture Collection (ATCC). 
The  ccRCC‐derived  cell  lines  SLR21,  SLR22,  SLR23,  SLR24,  SLR25  and  SLR26  were  kindly 
Materials and Methods 
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provided  by  W.J.  Storkus  (University  of  Pittsburgh,  USA).  Untransfected  and  stable 
transfectants of RCC4, 786‐O and A498 reexpressing pVHL and empty vector controls were 
previously  generated  [202,  203]  and  provided  by W.  Krek  (ETH  Zurich,  Switzerland).  The 
Burkitts’s  lymphoma cell  line Raji was kindly provided by M. Tinguely  (Institute of Surgical 
Pathology, University Hospital Zurich). Cell lines were grown under conditions recommended 
by ATCC and authenticated by short tandem repeat profiling by Identicell (Aarhus University, 
Denmark).  DMEM,  RPMI  and  K1  culture  media  were  supplemented  with  10%  FBS  (life 
technologies),  2  mM  L‐glutamine  (life  technologies),  100  μg/ml  streptomycin  (life 
technologies) and 100 U/ml penicillin (life technologies). Transfected cell lines were cultured 
in  the  presence  of  4  μg/ml  puromycin  (Sigma‐Aldrich;  RCC4)  or  500  μg/ml  geniticin  (life 
technologies; 786‐O and A498). For immune staining cell line pellets were formalin‐fixed and 
paraffin‐embedded as recently described [204]. For hypoxia experiments cells were incubated 
under  low‐oxygen  conditions  (0.5%)  in  a  hypoxic  workstation  (Invivo2  400;  Ruskinn 
Technology, Leeds, United Kingdom) for up to 24 hours. Cell lysates were harvested inside the 
chamber. Cell viability was measured by MTT assay (Roche). Metabolites were labeled by a 4‐





















NuPAGE  System  (Life  technologies). 50‐100  μg protein  in NuPAGE  LDS  sample buffer  (life 
technologies) and a size marker  (MagicMark XP and SeeBlue Plus2,  life technologies) were 
loaded on 4‐12%  gradient Bis‐Tris  gels  from  life  technologies  and  gel‐electrophoresis was 




































HA‐HIF1α‐pcDNA3.1 (+)  HIF1, HA‐tagged  Institute  of  Surgical  Pathology,  University
Hospital Zurich, Switzerland 










CD70 HRE1‐3‐pGL4.10  CD70 promoter (‐1887 to ‐1596 bp of Gene‐
ID: 970) 
cloned
CD70 HRE4‐7‐pGL4.10  CD70 promoter (‐1221 to ‐828 bp of Gene‐
ID: 970) 
cloned

















(Hs00154208_m1),  CD70  (Hs00174297_m1),  CD27  (Hs00386811_m1),  GLUT1 
(Hs00197884_m1),  HIF1  (Hs00936376_m1),  HIF2α  (Hs01026146_m1),  OCT4 
(Hs04260367_gH), PDK1 (Hs01561850_m1), PHD3 (Hs00222966_m1), PPIA (Hs99999904_m1) 




Chromatin  immunoprecipitation was  performed  according  the  protocol  (version  10.0)  of 
mammalian ChiP‐on‐chip  (Agilent Technologies). Briefly, 5x107‐1x108 cells were  fixed  in 1% 
formaldehyde, washed,  harvested  and  lysed.  The  cell  lysates were  sonicated  to  fragment 




































CD70  (Chromosome  19p13;  Gene‐ID:  970).  The  promoter  region  was  synthesized  from 
GenScript and cloned into firefly luciferase reporter plasmid pGL4.10 (Promega). Fragmented 
CD70 promoter constructs were cloned with primers from table 13 are listed in table 11. The 























Polymerase  (Thermo  Fisher  Scientific),  separated  by  size  in  an  1%  agarose  in  TAE  buffer 
(40 mM Tris, 20 mM acetic acid, 1 mM EDTA) gel containing gel red and made visible with UV 
light in an Gel Doc XR+ system (BioRad). The DNA was extracted from the gel (illustra GFX PCR 







incubated  for  15  minutes  on  ice.  Thereafter,  centrifugation  generated  cell  pellets  were 
resuspended  in  TFB2  buffer  (10 mM MOPS,  75 mM  calcium  chloride,  10 mM  rubidium 
chloride, 15 % glycerol, pH 6.8) and incubated on ice for 15 minutes. Aliquots of the competent 
bacteria were stored at ‐80°C.  
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Biology of Human Tumors
pVHL/HIF-Regulated CD70 Expression Is
Associated with Inﬁltration of CD27þ
Lymphocytes and Increased Serum Levels of
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Abstract
Purpose: CD70, a member of the TNF ligand superfamily, has
been shown frequently overexpressed in clear cell renal cell
carcinoma (ccRCC). The mechanisms of CD70's upregulation
and its role in ccRCC are unknown.
Experimental Design: CD70 expression was immunohisto-
chemically analyzed in 667 RCCs and RCC metastases. Von
Hippel–Lindau gene (VHL) mutations, expression patterns of
VHL protein (pVHL), hypoxia-inducible factor (HIF) a, and
several HIF targets were studied in tissues and cell lines and
correlated with CD70 overexpression. Gene promoter analysis
was performed to conﬁrm CD70 as HIF target gene. Consecutive
tissue sections were immunostained to reveal the relation
between CD70-expressing RCCs and tumor-inﬁltrating lympho-
cytes positive for the CD70 receptor (CD27). CD70-mediated
release of soluble CD27 in RCC was assessed by coculture experi-
ments and sera analysis of patients with RCC.
Results: Elevated CD70 expression was seen in 80% of primary
tumors and metastases of ccRCC and correlated with dysregula-
tionof the pVHL/HIFpathway. In vitro analyses demonstrated that
CD70 upregulation is driven by HIF. Furthermore, CD27þ lym-
phocytes preferentially inﬁltrate CD70-expressing ccRCCs. CD70-
dependent release of soluble CD27 in cocultures may explain the
high CD27 levels observed in sera of patients with CD70-expres-
sing ccRCC. The combination of lymphocyte inﬁltration and
CD70 expression in RCC was associated with worse patient
outcome.
Conclusion: Our ﬁndings demonstrate that in ccRCC, CD70
expression is regulated by HIF as a consequence of pVHL inac-
tivation. Increased serum levels of CD27 suggest the existence of
CD70-expressing ccRCC, thus representing a potential serum
marker for patients suffering from this disease. Clin Cancer Res;
21(4); 889–98. 2015 AACR.
Introduction
About 70% of clear cell renal cell carcinoma RCC (ccRCC), the
most common RCC subtype, harbor mutations in the von Hip-
pel–Lindau gene (VHL; ref. 1). Its gene product, pVHL, acts as an
adaptor protein for transcriptional regulation, the extracellular
matrix, and the microtubule cytoskeleton (2). The most promi-
nent function of pVHL is its role to target hypoxia-inducible factor
(HIF) a for ubiquitin-mediated proteolysis. The loss of function
of pVHL stabilizes HIFa and leads to the activation of a series of
genes, which encode proteins involved in angiogenesis, metab-
olism, and cell-cycle regulation. Among them are cell surface
proteins, including vascular endothelial growth factor and plate-
let-derived growth factor, which represent important therapy
targets for patients with ccRCC (3). However, these treatments
have signiﬁcant toxic side effects and response is only seen in a
subgroup of patients. To improve diagnosis, prognosis, and
treatment of patients with RCC, additional biomarkers, in par-
ticular cell surface proteins, would be of utmost importance.
CD70 is a member of the TNF ligand superfamily and caught
our interest because it was one of the ccRCC surface proteins we
previously identiﬁed by cell surface capturing technology (4).
Under normal conditions, CD70 expression is tightly regulated
and restricted to a small subset of antigen-stimulated B and T
lymphocytes and mature dendritic cells (5, 6). The interaction of
CD70 with its receptor CD27 promotes expansion and differen-
tiation of memory and effector T cells as well as B-cell expansion
and plasma cell differentiation (7, 8). Altered CD70 expression
was found in hematologic malignancies and also in solid tumors,
such as nasopharyngeal carcinoma, thymic carcinoma, and brain
tumors (9). The most frequent expression was reported in RCC
(10–13), but the mechanism that leads to the upregulation of
CD70 in this tumor type is still unclear. Interestingly, CD70
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expression is less prevalent in VHL unrelated RCC subtypes.
Studies elucidating the consequences of the constitutive expres-
sion of CD70 and its interaction with CD27 in ccRCC are rare and
controversial. Although some authors hypothesized that CD70 is
involved in an immune escape mechanism of RCC by mediating
apoptosis in lymphocytes (14), others suggested that CD70 rather
triggers a phenotypic conversion of CD27þ tumor-inﬁltrating
lymphocytes (TIL) into a more differentiated state (15).
Here, we studied the impact of pVHL and HIFa on CD70
expression as well as the role of CD27-expressing TILs in ccRCC
by (i) analyzingCD70expressionpatterns in a large cohort of RCC
tissues, (ii) investigating the interrelation of CD70 expression and
the pVHL-HIFa axis by VHL mutation analysis and in vitro
experiments, (iii) determining CD27 mRNA and protein expres-
sion in TILs and its correlation with the CD70 expression status,
and (iv) examining the concentration of soluble CD27 (sCD27)




For immunohistochemical (IHC) analyses, tissue microar-
rays (TMA) with 252 ccRCCs (4) and 54 ccRCC brain metas-
tases (16, 17) from the Institute of Surgical Pathology, Uni-
versity Hospital of Zurich, Switzerland, and a TMA comprising
348 papillary RCCs (18) from the University of Erlangen,
Erlangen, Germany, were used. Each TMA was histologically
reviewed by one pathologist (H. Moch and A. Hartmann,
respectively). Clinicopathological parameters of the ﬁrst TMA
have already been described (19). This study was approved by
the local ethics commission (reference no. StV38-2005).
Human blood samples of 54 patients, who underwent full or
partial nephrectomy as part of their standard treatment at the
Department of Urology, University Hospital Zurich (Zurich,
Switzerland), were collected on the day of surgery following
informed consent. Serum was processed according to a stan-
dardized protocol. Sera of 17 healthy persons served as control.
Formalin-ﬁxed, parafﬁn-embedded tissue samples from these
patients were also available. This study was approved by the
local ethics commission (KEK-ZH no. 2011-0072/4).
IHC
TMA and whole tumor sections (2.5 mm) were IHC-stained
according to Ventana automat protocols (Ventana Medical Sys-
tem). The antibodies applied for detection are listed in Supple-
mentary Table S1. The staining intensities were classiﬁed as
absent, moderate, and strong. Lymphocyte inﬁltration was ana-
lyzed using hematoxylin and eosin-stained large sections and was
scored as absent, sparse to loose and dense inﬁltrate. For detailed
analysis, TMAswere scanned using theNanoZoomerDigital Slide
Scanner (Hamamatsu Photonics K.K.).
VHL mutation analysis
VHLmutation analysis of cell lines and tissues was performed
as described (1). Cell line VHL mutations are listed in Supple-
mentary Table S2. The program Site Directed Mutator (SDM) was
used to predict the association of VHL missense mutations and
disease as described (1).
Gene expression analysis
Gene expression data of 116 RCCs and six normal kidneys were
obtained from a recently publishedmicroarray study (20).Micro-
array data are available in Gene Expression Omnibus under
GSE19949.
Cell lines
The RCC-derived cell lines ACHN, A498, A704, Caki-1, Caki-2,
HK-2, KC12, 769P, 786-O and the human embryonic kidney cell
line HEK-293 were supplied by ATCC. RCC4, SLR21 to SLR26
were kindly provided by W. Krek (ETH Zurich, Switzerland) and
W.J. Storkus (University of Pittsburgh, Pittsburgh, PA), respec-
tively. Stable transfectants of 786-O and A498 reexpressing pVHL
and empty vector controls were previously generated (21, 22).
Cell lines were grown under conditions recommended by ATCC
and authenticated by short tandem repeat proﬁling by Identicell
(Aarhus University, Aarhus, Denmark). For immune staining, cell
line pellets were formalin ﬁxed and parafﬁn embedded as recently
described (23). For hypoxia experiments, cells were incubated
under low-oxygen conditions (0.5%) in a hypoxic workstation
(Invivo2 400; Ruskinn Technology) for up to 24 hours.
Immunoblot analysis
Preparation of cell lysates, determination of protein concen-
tration, and Western blotting were performed as described (4).
Antibodies used are listed in Supplementary Table S1. For remov-
al of N-glycans, PNGase F (New England Biolabs) was used.
Transient transfections
For RNAi experiments, cells were transfected with 5 nmol/L
siRNA (HIF1a, HIF2a, and scrambled) as described (24). For
silencing of CD70, Hs_TNFSF7_1;_2;_3, and Hs_CD70_1
(00748699, SI00748706, SI00748713, SI04277182, Qiagen)
were used.
To study the effects of HIFa overexpression, RCC cells were
transfected with 5 mg HIF1a, HIF2a, or HIF2a DNA-binding
mutant (25) in pcDNA3.1 using XtremeGene HP (Roche) and
grown for 24 hours in a six-well format. The mutant HIF2a
construct was kindly provided by P. Ratcliffe (University of
Oxford, Oxford, United Kingdom).
Translational Relevance
The deregulation of the von Hippel–Lindau protein
(pVHL)/hypoxia-inducible factor (HIF) axis is a hallmark of
clear cell renal cell carcinoma (ccRCC). Consequently, protein
products of HIF-regulated genes are considered potential
therapeutic targets of this tumor type. We have found that in
ccRCC, abundant and frequent CD70 expression is directly
driven by HIF. Furthermore, we observed a close relationship
between CD70 overexpression and CD70 receptor (CD27)þ
inﬁltrating lymphocytes, which seems to be linked to a more
aggressive biologic behavior. Coculturing of pVHL-negative
and pVHL-reexpressing RCC cell lines with peripheral blood
mononuclear cells demonstrated signiﬁcant increase of solu-
ble CD27 levels in the presence of CD70. Thismaybe the cause
for the high soluble CD27 levels observed in the sera of
patients with CD70-expressing ccRCC inﬁltrated by CD27þ
lymphocytes, thus suggesting soluble CD27 as a diagnostic
tool for ccRCC patient monitoring.
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Quantitative reverse transcription-PCR
RNA isolation, cDNA synthesis, and quantitative reverse tran-
scription-PCR (qPCR) were performed as described (4). TaqMan
Gene Assays (Applied Biosystems) for CA-IX (Hs00154208_m1),
CD70 (Hs00174297_m1), CD27 (Hs00386811_m1), GLUT1
(Hs00197884_m1), HIF1a (Hs00936376_m1), HIF2a
(Hs01026146_m1), OCT4 (Hs04260367_gH), PDK1
(Hs01561850_m1), PHD3 (Hs00222966_m1), PPIA
(Hs99999904_m1), and VHL (Hs00184451_m1) were used.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed as
described (5). Fragments of 100-600 bp of cellular DNA were
incubated with a HIFa-antibody/magnetic bead (Dynabeads
Protein G; Invitrogen) mixture. SYBR Green real-time PCR was
performed to quantify the differential binding of HIFa to the
hypoxia-responsive elements (HRE) of CD70. The antibody and
primers used for the ChIP experiments are listed in Supplemen-
tary Tables S1 and S3.
Luciferase gene reporter assay
The nucleotides between2,000 andþ700were deﬁned as the
putative promoter region of CD70 (Chr 19p13; Gene-ID: 970).
The promoter region was synthesized from GenScript and cloned
into ﬁreﬂy luciferase reporter plasmid pGL4.10 (Promega). The
positive control P2P contains the P2P HREs of the human PHD2
promoter (26) and were provided by R. Wenger (University of
Zurich). Luciferase activity was measured 24 hours after transfec-
tion of A498 empty vector and A498 reexpressing pVHL with 1 mg
of reporter plasmids along with 200 ng of pGL4.74 Renilla
luciferase reporter plasmid in 24-well plates. HIFaoverexpression
was performed 48 hours before measurement. Relative luciferase
units were determined according to the manufacturer's instruc-
tions (Dual luciferase reporter assay system, Promega).
Determination of sCD27 in cocultures and sera of patients with
RCC
TheRCC cellswere seeded into sixwells that the number of cells
reached 2.7 105/well 48 hours later. For siRNA experiments, cell
transfection was performed 24 hours after seeding. Peripheral
blood mononuclear cells (PBMC) of a healthy individual were
isolated by Ficoll (GE Healthcare) density centrifugation. Forty-
eight hours after seeding and repeated washing, 2.7 106 PBMCs
were added in 2 mL RPMI-1640 containing 10% FCS. The cells
were cocultured for 2 additional days. PBMCs and RCC cells were
maintained inmonoculture in parallel. After 2 days, supernatants
were used to analyze sCD27 concentration by sandwich ELISA
(M1960, Sanquin) according to the manufacturer's instructions.
The different experimental approaches were performed using
PBMCs of different healthy individuals (donor A-C). The sCD27
ELISA was also used for testing sera of patients with RCC and
healthy individuals.
Statistical and computational analyses
The Pearson c2 test, Fisher exact test, Student t test, and survival
analysis were performed using SPSS Statistics 21 (IBM). Correla-
tion analysis (Pearson R) was performed using GraphPad Prism 5
(GraphPad Software).
Results
CD70 is frequently expressed in ccRCC and ccRCC metastasis
Gene expression analysis of 116 RCC tissues (20) revealed that
CD70was upregulated in primary andmetastatic ccRCC (Fig. 1A).
Using TMAs containing a total of 667 RCCs, we observed high
Figure 1.
CD70 expression pattern in RCC. A,
CD70 gene expression in 116 RCCs and
six normal kidney tissues. T tests were
performed. B, representative pictures
of anti–CD70-immunostained
ccRCCs and papillary RCCs (40
magniﬁcation, bars: 20 mm). C,
histogram representing CD70
expression intensities in RCC and
normal kidney tissue. The Pearson
c2 test or Fisher exact test was
performed. D, representative pictures
of anti–CD70-immunostained
localized ccRCC and corresponding
brain metastasis (n ¼ 8,20
magniﬁcation, bars, 50 mm). pap,
papillary; chromo, chromophobe;
met, metastasis;  , P < 0.0001;
 , P < 0.005;  , P < 0.05; ns, not
signiﬁcant.
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CD70 protein expression in 78% of ccRCCs, but in only 32% of
papillary RCC. Oncocytomas, chromophobe RCCs, and normal
kidneys were negative (Fig. 1B and C). Furthermore, 54 ccRCC
brain metastases showed a similar CD70 expression frequency as
observed inprimary tumors.Notably, the strongCD70 expression
seen in nine primary ccRCC remained constant in their corre-
sponding brain metastasis (Fig. 1D).
CD70 expression andVHLmutation status in ccRCC tissues and
cell lines
Many VHL mutations are thought to inactivate pVHL's func-
tional integrity in ccRCC. To test whether VHL mutations affect
CD70expression,we correlated themRNAandprotein expression
patterns of CD70 with VHL mutation data in a series of ccRCCs,
which were recently published by our group (1). Although VHL
wild-type (wt) ccRCC may also have lost pVHL activity due to
hypermethylation of its gene promoter, we found an association
of CD70 expression and mutated VHL (Fig. 2A and B). CD70
expression was even more frequent in tumors with VHL muta-
tions, which predict impaired function of pVHL compared with
tumors with VHLwt and VHLmutations not affecting the protein
function (Fig. 2C). We conﬁrmed these ﬁndings in RCC cell lines
with different VHL and HIF1a mutation states (ref. 27; Supple-
mentary table S2). CD70mRNA and protein levels were generally
higher in RCC cell lines harboring VHL loss-of-function muta-
tions (Caki-2, SLR22, SLR23, A498, 786-O, and KC12) and VHL
missensemutations predicted to affect the pVHL function (RCC4,
SLR24, and SLR26). RCC cell lines with VHLmissense mutations
having no functional impact on the protein (SLR25, 769P, and
A704) and those with wt VHL (SLR21, ACHN, Caki-1, HK-2, and
HEK293) showed no or only weak CD70 expression (Fig. 2D–F).
CD70expressionwasmainly observed in cell lines that eitherwere
HIF1a-, HIF2a- or HIF1a- andHIF2a-positive. Inmost of the cell
lines that express CD70, Glut1 and CA-IX were also present (Fig.
2E). This was also true on mRNA level, the CD70 expression
correlated with GLUT1 and CA-IX, but was not associated with
other HIF target genes (PDK1, OCT4, and PHD3; Fig. 2D). The
multiple banding pattern of CD70 in RCC seen on Western blot
analyses was also previously described (13, 28) and results largely
from N-linked glycosylation (Supplementary Fig. S1).
CD70 expression is dependent of the pVHL/HIFa axis in RCC
tissue and cell lines
To evaluate the impact of pVHL andHIF onCD70 expression in
RCC,weﬁrst performed qPCR (Fig. 3A) andWestern blot analyses
(Fig. 3B) of pVHL-deﬁcient RCC cell lines 786-O and A498 and
Figure 2.
Association of CD70 with the VHL
mutation status. A, CD70 gene
expression in ccRCC tissue with
mutated or wt VHL.  , P < 0.001 by
t test. B, histogram representing
CD70 expression intensities in ccRCCs
with mutated or wt VHL. ns, not
signiﬁcant by Pearson c2 test. C, CD70
expression intensities assigned to
ccRCC tissue with function of pVHL
predicted to be impaired or not
impaired. In silico analysis was done
with SDM.  , P < 0.05 by Pearson
c2 test. D, mRNA levels of CD70, the
HIF1a-dependent genes CA-IX and
PDK1, the HIF2a-dependent genes
GLUT1, OCT4, and PHD3; (E) Western
blot analysis of HIF1a, HIF2a, CD70,
CA-IX, and Glut1; and (F) cell
microarray stained for CD70 in
different RCC cell lines (20
magniﬁcation; bar, 20 mm). The VHL
mutation status is indicated as wt, loss
of function (lof), missense (ms) with
(ﬁ) and without (no ﬁ) functional
impact on pVHL.
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their stable transfectants reexpressing pVHL. Reconstituted pVHL
lead to a decrease of the CD70 expression and the HIF targets CA-
IX, GLUT1, OCT4, and PHD3. TMA analyses demonstrated a
signiﬁcant association of CD70 expression and pVHL/HIF dereg-
ulation. CD70 expression was directly correlated with the expres-
sion of HIF1a (P¼ 0.0136, Pearson R¼ 0.1359) and HIF2a (P <
0.0001, Pearson R¼ 0.2833) as well as with the HIF targets CA-IX
(P < 0.0001, Pearson R¼ 0.4267), Glut1 (P < 0.0001, Pearson R¼
0.4093), and CD10 (ref. 4; P < 0.0001, Pearson R ¼ 0.3901). An
inverse correlation was seen with pVHL (P¼ 0.0144, Pearson R¼
0.1398) and E-Cadherin (P ¼ 0.0485, Pearson R ¼ 0.1121).
CD70 expression alone was not associated with grade, stage, and
survival in ccRCC (data not shown). Silencing ofHIF2a in 786-O
and A498 exclusively expressing HIF2a (but not HIF1a) lead to a
decrease of CD70 mRNA and protein expression (Fig. 3C–F).
In SLR22, CD70 downregulation was achieved only when
both HIF1a and HIF2a were silenced (Supplementary Fig.
S2A). Following transient overexpression of HIF1a and HIF2a
in 786-O andA498, an increase ofCD70mRNAandprotein levels
was observed (Fig. 3G and H). Even in the pVHL-defective RCC
cell lines SLR22 and SLR24 with low endogenous CD70 levels,
upregulation of the latter could be induced by overexpression of
HIF2a (Supplementary Fig. S2B and S2C). In pVHL-negative and
-positive 786-O and A498 cells, CD70 expression was continu-
ously increasing under hypoxia within the ﬁrst 12 hours (Fig. 3H
and I).
Figure 3.
CD70 expression is dependent on the
pVHL/HIF axis. A, mRNA levels of VHL,
CD70, CA-IX, GLUT1, OCT4, and PHD3
in 786-O and A498 with reconstituted
pVHL relative to empty vector
obtained by qPCR. B, Western blot
analysis of HIF2a, CD70, and pVHL in
786-O and A498 with reconstituted
pVHL or empty vector. C, mRNA levels
of CD70, CA-IX, GLUT1, OCT4, PHD3,
and HIF2a relative to control siRNA
(siScr) obtained by qPCR and (D)
Western blot analysis of HIF2a and
CD70 in 786-O, and (E) A498 after
silencing of HIF2a for 48 and 72 hours.
F, mRNA levels of CD70, CA-IX, HIF1a,
and HIF2a relative to empty vector
control obtained by qPCR and (G)
Western blot analysis of HIF1a, HIF2a,
CA-IX, and CD70 in 786-O after
transient overexpression of HIF1a and
HIF2a. H, Western blot analysis of
HIF2a and CD70 in 786-O and (I) A498
with and without reconstituted pVHL
incubated at 0.5% oxygen for 0, 2, 4, 6,
12, and 24 hours (h). Error bars, SD
(n ¼ 3).
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CD70 expression is directly regulated by HIF
To elucidate whether CD70 represents a potential HIF target,
we investigated HIF's ability to bind to the eight potential HREs
residing in 2.7 kb of the putative promoter of CD70 (Fig. 4A) by
ChIP using HIF2a-, HIF1a-, and the corresponding isotype
control- antibodies (Fig. 4B and C). The reconstitution of pVHL
in 786-O, A498, and RCC4 leads to a reduction of the direct
binding of HIF2a and HIF1a to HRE3, 4, and 8 in the CD70
promoter. No binding was observed for the negative control
gene KCNJ5. CD10 HRE2 served as positive control for HIF1a
binding (4).
To conﬁrm this ﬁnding, we performed luciferase reporter gene
assays. For this purpose, the DNA fragment containing the 50-
region of CD70 (2000/þ700) was inserted upstream of the
luciferase gene. Compared with pVHL reexpressing A498 cells,
the luciferase activity of the CD70 reporter gene construct was
increased in A498 empty vector cells to the same extent as for the
HIF target gene PHD2 promoter construct (P2P; Fig. 4D).The
same effect was seen by overexpression of HIF2a in A498, but not
by overexpression of its DNA-binding mutant (ref. 25; Fig. 4E),
which is unable to induce the expression of the CD70 protein
product (Supplementary Fig. S2D and S2E).
Preferential inﬁltration of CD27þ lymphocytes in CD70-
expressing tumors
As the role of CD70–CD27 interaction in ccRCC is unknown,
we next asked whether there was an association between CD70-
expressing tumor cells and CD27þ TILs. qPCR analysis of 47
ccRCCs selected from the TMA, which was immunostained
against CD70, showed higher CD27mRNA expression in tumors
with strong CD70 staining compared with tumors with lower
CD70 expression (Fig. 5A). CD27 and CD70 gene expression
obtained from a recent DNA-microarray analysis (20) conﬁrmed
this ﬁnding (Fig. 5B). To validate the gene expression data on
protein level, we investigated CD70 and CD27 expression
patterns on large consecutive tissue sections of 41 ccRCC
inﬁltrated by lymphocytes. We observed that 37 ccRCCs
(90%) contained also CD27þ lymphocytes (Fig. 5C). Interest-
ingly, correlations between TMA expression data and clinico-
pathological data showed that patients with CD70-negative
ccRCCs and no lymphocyte inﬁltration had a better survival
compared with those with CD70 strongly positive and lym-
phocyte-inﬁltrated ccRCCs (P < 0.05; Fig. 5D). The latter
tumors were signiﬁcantly associated with a high Fuhrman grade
(P < 0.0001) but not with late tumor stage (Supplementary
table S4). The strong correlation between CD27 and the sub-
units of the T-cell marker CD3 indicates that the CD27-stained
lymphocytes were T cells (Supplementary Fig. S3).
PBMCs trigger the release of sCD27 in a CD70-dependent
manner
CD27 is known to be cleaved by a protease into its soluble form
sCD27 on activated T cells (29, 30). It was also shown that CD70-
expressing glioma cells enhance the release of sCD27 fromPBMCs
(28). To test whether CD27 can also be cleaved after interaction
with CD70 in RCC, we cocultured RCC cells with freshly isolated
PBMCs and measured sCD27 in the supernatant by ELISA (Fig.
6A). Supernatants of PBMCandRCCcellmonocultures contained
basic levels of sCD27 after 2 days. PBMC cocultures with the
CD70-expressing cell lines 786-O, A498, and SLR23 signiﬁcantly
increased the sCD27 concentration (2.7-fold, 1.9-fold, and 2.3-
fold, respectively). This increase correlated with the PBMC/RCC
cells ratio (Supplementary Fig. S4A). Cocultures with CD70 low-
expressing cell lines Caki-2, SLR22, SLR24, and SLR25 had only
slightly elevated sCD27 concentration levels compared with
PBMC monocultures. Both CD70 silencing (Supplementary
Figure 4.
CD70 promoter binding and gene
expression by HIFa. A, schematic
representation of the 2.7 kb CD70
promoter with the location of six HREs
and two reverse HREs (rHRE). B,
binding of HIF2a and (C) HIF1a at the
CD70 promoter relative to its isotype
controls analyzed by ChIP. HRE1-8
indicates in silico identiﬁedHREs in the
CD70 promoter; KCNJ5 served as
negative and CD10 HRE2 as positive
control for HIF1a. Results are shown as
ratios of the amplicons detected in
786-O, A498, or RCC4 pVHL-positive
and negative relative to HRE1. D,
luciferase induction of the 2.7 kb
promoter region of CD70 in A498
empty vector relative to A498
reconstituted with pVHL and (E) after
overexpression of HIF2a or a DNA
binding mutant of HIF2a in A498
relative to pcDNA3.1-transfected cells.
P2P served as a positive control for the
HIF activity. (vector ¼ empty
luciferase reporter plasmid pGL4.10).
Error bars, SD (n ¼ 3).
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Fig. S4B and S4C) and reconstitution of pVHL in 786-O and A498
cells caused a reduction of sCD27 levels (Fig. 6A).
Elevated sCD27 levels are detectable in sera of patients with
CD70-expressing RCC
To investigate whether our in vitro results were conferrable to
patients, wemeasured sCD27 concentration in sera of ccRCC and
papillary RCC patients and healthy individuals (Fig. 6B). sCD27
levels were compared with the expression status of CD27 and
CD70 on large tissue sections of the corresponding patients (Fig.
6C). sCD27 serum levels of patients with CD70-expressing tumor
cells and CD27þ TILs were signiﬁcantly higher compared with
those of healthy individuals and RCCs of patients that either had
CD70-positive tumor cells but no CD27þ TILs or had CD27þ TILs
and CD70-negative tumor cells or were negative for both.
Notably, ELISA analysis of CD70 revealed that CD70 protein
expression levels in 31 RCCswere not reﬂected in the sera of these
patients asmost of the CD70 levels were below the detection limit
(data not shown).
Discussion
In this study, we demonstrated that the high and frequent
CD70 expression in ccRCC is driven by HIF as a consequence of
pVHL loss of function. We further observed a strong association
between CD70-expressing tumor cells and the presence of CD27þ
T cells in TILs. The ability of CD70 to trigger the release of sCD27
on PBMCs in vitro and the increased levels of sCD27 in the sera of
patients with CD70-expressing tumors suggest that sCD27 is a
putative serum marker for CD70-positive ccRCC patients.
CD70 expression is dependent on the RCC subtype. IHC TMA
staining of more than 600 RCCs showed abnormal CD70 expres-
sion in 78% of ccRCCs, which was consistent with previously
described frequencies (11, 12). Our comprehensive CD70 anal-
ysis of 348 papillary RCCs revealed 11% strongly and 22%
moderately expressing tumors, which was lower compared with
the frequencies observed in recently published smaller cohorts
(10, 12, 13). No expression was seen in 21 oncocytomas and
13 chromophobe RCCs suggesting a negligible role of CD70 in
these tumor subtypes.
We show that the abnormal upregulation of CD70 in ccRCC is
closely related to the deregulation of the pVHL/HIF axis. CD70
expression patterns in RCC tissue were signiﬁcantly correlated
with those seen for HIFa and the HIF targets CA-IX, Glut1, and
CD10. The analysis of the mutation status of VHL in 363 ccRCCs
and 17 RCC cell lines further supported the association of CD70
expression withVHL sequence alterations. High CD70 expression
levels were signiﬁcantly linked to VHLmutations that very likely
abrogate pVHL's function. Inactivation of VHL by hypermethyla-
tion of its promoter (31) andmissensemutations with no or only
minor effects on pVHL's ability to bind HIFa (1) may explain the
presence or absence of CD70 in several VHL wt and mutated
tumors, respectively. In pVHL-affected cell lines, the expression
pattern of CD70 was comparable with that of HIF1a, HIF2a as
well asHIF targetsGlut1 andCA-IX.Our results suggest that CD70
is driven by both HIF1a and HIF2a. Some pVHL-deﬁcient ccRCC
Figure 5.
Correlation between CD70 expression and
CD27þ TILs. A, CD27 mRNA levels obtained
by qPCR separated into ccRCCs showing no,
moderate, or strong CD70 tumor staining on
TMA. B, CD70 plotted against CD27 mRNA
levels of the gene expression data. Pearson R
correlation analyses are depicted. (met,
metastasis). C, representative pictures of
anti-CD70 and anti–CD27-immunostained
ccRCCs of consecutive slides (40
magniﬁcation; bar, 100 mm). D, Kaplan–Meier
plot of the overall survival of ccRCC patients
deﬁned by the CD70 expression
accompanied by lymphocyte inﬁltration.
A log-rank test was performed.
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cell lines exhibited elevated HIFa although CD70 was absent.
They may resemble those 20% (34/174) of CD70-negative
ccRCCs, which had VHL mutations with functional impact on
pVHL, presumably causing HIFa stabilization. Epigenetic regu-
lation of HIF-binding sites can probably inﬂuence the transcrip-
tional response tohypoxia (32). AberrantDNAmethylationof the
two CpG islands (993 to323 bp relative to transcription start
site; ref. 33), which overlap the region with the putative HREs in
theCD70 promoter, may thus prevent HIF from binding andmay
explain why CD70 is not or only weakly expressed in the presence
of HIF in those tumors.
In vitro experiments, which includedpVHL reconstitution,HIFa
silencing and overexpression, hypoxia experiments, ChIP and
luciferase assays conﬁrmed that CD70 expression is dependent
on pVHL's functional integrity and the transcriptional activation
byHIF. The attenuationofCD70protein expression after 12hours
under hypoxic conditions may be caused by oxygen-sensitive
pathways that are HIF-independent (34).
It is obvious that in ccRCC, the mechanism of CD70's upre-
gulation is different to that reported in several T-cell affecting
diseases, such as systemic lupus erythematosus and systemic
sclerosis (35, 36) in which hypomethylation of the CD70 pro-
moter contributes to CD70 overexpression. Using the samemeth-
ylation-speciﬁc PCR protocol described by Yu and colleagues
(33), no hypomethylation of the CD70 promoter was seen in
ccRCC tissues, which strongly expressed CD70 (data not shown).
This suggests that the transcriptional regulation of CD70 is rather
driven by HIF and does not depend on promoter hypomethyla-
tion in this tumor subtype.
A strong relationship between HIFa activation, CD70 upregu-
lation, and tumor formation was demonstrated in TRACK mice
(transgenic model of cancer of the kidney), which speciﬁcally
express a mutated, constitutively active form of HIF1a in kidney
proximal tubule cells (37). Activated HIF1a was sufﬁcient to
promote phenotypic alterations characteristic of human VHL
ccRCC, including upregulation of CA-IX, Glut1, and CD70,
whereas a constitutively activated form of HIF2awas neither able
to promote ccRCC nor to enhance the expression of CD70 (38).
This stands in contrast with the ﬁndings of Gordan and colleagues
(39) who showed that HIF2a rather than HIF1amediates ccRCC
progression. Our in vitro data indicate that CD70 can be activated
by both HIFa isoforms. However, strong CD70 expression is
preferentially seen in RCC cell lines in which only HIF2a is
present suggesting that HIF2a is a key regulator for CD70 expres-
sion in progressing ccRCC.
In addition to the mechanisms for abnormal CD70 expression
in ccRCC, we were also interested to investigate the role of the
interaction with its receptor CD27, which is known to be
expressed on the surface of memory B cells, na€ve, and activated
T cells and a subset of natural killer (NK) cells (7).Microarray gene
expression data of ccRCC revealed a signiﬁcant correlation
between CD70 and CD27 expression. A detailed IHC analysis of
large ccRCC tissue sections demonstrated that the lymphocyte
inﬁltrates in CD70-expressing tumors were almost always accom-
panied by CD27þ TILs.
Neither we nor others have found a strong correlation between
CD70 expression alone and tumor grade, stage, and patient
survival (12, 13). As the loss of pVHL function is considered an
early event in ccRCC (3), the subsequent upregulation of CD70
may also contribute to tumor formation. We observed that the
frequency of strong CD70 expression in pVHL-deﬁcient primary
ccRCC is retained in metastatic lesions. It is therefore conceivable
that the persistent expression of CD70 in tumors leads to an
enhanced attraction and inﬁltration of CD27þ lymphocytes.
Interestingly, ccRCC with strong CD70 expression and TILs had
a higher nuclear differentiation grade and a signiﬁcantly worse
Figure 6.
Release of sCD27 via CD70 in vitro and
high serum levels of sCD27 in
CD70-expressing RCC patients.
A, concentrations of sCD27 in
supernatants of PBMC and RCC cell
line cocultures or monocultures were
determined by ELISA. In 786-O and
A498, CD70 expression was silenced
by siRNA (siCD70#1–4). siScr, control
siRNA. Donor A–C, PBMCs from
different healthy individuals. B, sCD27
serum concentrations of patients
with RCC and healthy controls.
, P < 0.005 by the t test. C,
representative pictures of anti-CD70
and anti–CD27-immunostained
ccRCCs of consecutive slides of large
sections (40 magniﬁcation; bar,
100 mm). The existence of CD70
expression and CD27þ inﬁltrations
(CD70/CD27) of the tumor tissueswas
indicated as absent () or present (þ).
D, a model showing the biologic and
clinical relevance of CD70 and CD27 in
ccRCC.
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survival compared with CD70-negative tumors that were not
inﬁltrated by lymphocytes. On the basis of this ﬁnding, we
conclude that the interaction of CD70-expressing tumor cells and
CD27þ TILs may play a role in tumor progression.
Different tumor-promotingmechanisms have been proposed in
this context. sCD27 can induce proliferation in CD70-positive
acute lymphoblastic leukemia and nasal NK/T-cell lymphoma
(40, 41). It was therefore tempting to speculate that the interaction
ofCD27þ TILswithCD70present on ccRCC cells has similar effects
and accelerate tumor growth. Both sCD27 (42) and CD70 (8)
contribute toT-cell activationandproliferation.However,we could
not see any proliferative effects of recombinant sCD27 in response
to CD70 in two RCC cell lines (data not shown). Second, although
CD70-expressing ccRCC and glioma cells were able to provoke T-
cell apoptosis in coculture experiments (14, 28, 43), the immune
inhibitory properties of CD70 in vitro seem to be clearly over-
whelmed by the immune activating properties observed in mouse
glioma models in vivo (44). Finally, the chronic ligation of CD27
and CD70 may also lead to T-cell exhaustion, a kind of "immune
escape." It was shown that constitutive expression of CD70 on B
cells inmice converted na€ve T cells into effectormemory cells. This
culminated in the depletion of na€ve T cells, which lead to lethal
immunodeﬁciency (45). In keepingwith this,Wang and colleagues
observed less na€ve and central memory T-cell subpopulations but
more effector memory cells in ccRCC in contrast with peripheral
blood lymphocytes and melanoma (15). They suggested that this
phenotypic conversion of T cell is caused by high CD70 expression
in ccRCC. These results together with our ﬁndings suggest that the
coexistence of CD70 and CD27 in ccRCC fosters immune exhaus-
tion effects by chronic costimulation.
As it was shown with glioma cells (28), coculturing of PBMCs
with RCC cells resulted in a CD70-dependent increase of
sCD27 in the supernatant. A similar effect may occur in
CD70-expressing ccRCC tissue with CD27þ TILs because the
levels of sCD27 in sera of those patients were signiﬁcantly
higher compared with patients with CD70- and CD27-negative
tumors and healthy persons. Besides lymphoid malignancies
(40, 41), ccRCC is the ﬁrst solid tumor type in which increased
serum levels of sCD27 have been observed. High serum con-
centration of sCD27 may thus represent a potential predictive
marker in patients with ccRCC, which indirectly indicates the
presence of CD70-expressing tumors.
In conclusion, we demonstrated that in pVHL-deﬁcient ccRCC,
CD70 is upregulated via HIF. A model illustrating our hypothesis
is shown in Fig. 6D. CD70 and CD27 interaction seems to boost
the release of sCD27 in sera of patients with ccRCC suggesting
CD27 a potential prognostic and diagnostic marker that may also
be used to predict the applicability of CD70-targeted therapies or
CD27-targeted immunotherapies (46). At the moment, three
novel anti-CD70 antibody–drug conjugates are under evaluation
for metastatic ccRCC in clinical trial phase I (47), which have
shown promising antitumor activity in CD70-expressing RCC
mouse xenografts (48). One should, however, bear in mind that
blocking of CD70–CD27 interaction by CD70-targeting drugs
may impede de novo T-cell priming (49, 50), thus hampering
patients' immune response capability.
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Abstract
Mass spectrometry analysis of renal cancer cell lines recently suggested that the protein-tyrosine phosphatase
receptor type J (PTPRJ), an important regulator of tyrosine kinase receptors, is tightly linked to the von
Hippel–Lindau protein (pVHL). Therefore, we aimed to characterize the biological relevance of PTPRJ for clear
cell renal cell carcinoma (ccRCC). In pVHL-negative ccRCC cell lines, both RNA and protein expression levels of
PTPRJ were lower than those in the corresponding pVHL reconstituted cells. Quantitative RT-PCR and western
blot analysis of ccRCC with known VHL mutation status and normal matched tissues as well as RNA in situ
hybridization on a tissue microarray (TMA) confirmed a decrease of PTPRJ expression in more than 80% of
ccRCCs, but in only 12% of papillary RCCs. ccRCC patients with no or reduced PTPRJ mRNA expression had a
less favourable outcome than those with a normal expression status (p = 0.05). Sequence analysis of 32 PTPRJ
mRNA-negative ccRCC samples showed five known polymorphisms but no mutations, implying other mechanisms
leading to PTPRJ’s down-regulation. Selective silencing of HIF-α by siRNA and reporter gene assays demonstrated
that pVHL inactivation reduces PTPRJ expression through a HIF-dependent mechanism, which is mainly driven by
HIF-2α stabilization. Our results suggest PTPRJ as a member of a pVHL-controlled pathway whose suppression by
HIF is critical for ccRCC development.
Copyright  2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
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Introduction
Most clear cell renal cell carcinomas (ccRCCs) are
characterized by a bi-allelic somatic inactivation of
the von Hippel–Lindau (VHL) tumour suppressor
gene [1]. The VHL protein (pVHL) is an important
regulator of the hypoxia inducible factor-α (HIF-
α), microtubule stabilization, maintenance of the
primary cilium, mitotic regulation, and cell mobil-
ity [2]. Loss of function of pVHL leads to HIF-α
stabilization and up-regulation of HIF target genes
which are involved in cell growth and proliferation,
angiogenesis, invasion, and metastasis. Examples of
up-regulated HIF-target genes are VEGF-A, EPO ,
EGFR, and CAIX [3], which also represent potential
anti-cancer drug targets. Data about genes and proteins
down-regulated due to pVHL functional deficiency
are rare. Examples include important genes/proteins
such as fibronectin [4], E-cadherin [5], PAX2 [6], and
p53 [7].
Recent mass spectrometry experiments with ccRCC
cell lines [8] showed that the expression of the pro-
tein tyrosine phosphatase receptor type J (PTPRJ) is
associated with the presence of pVHL. PTPRJ is com-
posed of an extracellular domain that contains eight
fibronectin type III repeats, a transmembrane domain,
and a cytoplasmic end comprising a single catalytic
domain [9]. In vitro, the receptor is involved in the reg-
ulation of cellular differentiation, proliferation, growth,
and migration [10–14], which supports its potential rel-
evance for cancer development. In colon, lung, and
breast cancer, PTPRJ is affected by allelic imbal-
ances and missense mutations [15,16]. Furthermore,
several membrane-associated tyrosine kinase receptors
are controlled by PTPRJ; among them there are estab-
lished or potential molecular anti-cancer drug targets,
eg EGFR [17], PDGFR-β [18], VEGFR2 [19], and
HGFR (also termed c-MET) [20].
To date, the molecular mechanisms leading to
down-regulation of PTPRJ expression in ccRCC are
Copyright  2012 Pathological Society of Great Britain and Ireland. J Pathol 2013; 229: 525–534
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unknown. Consequently, here we have investigated the
influence of the pVHL–HIF axis on PTPRJ expression
in human ccRCC.
Materials and methods
Tissue specimens and tissue microarray
For quantitative RT-PCR analysis of PTPRJ mRNA
levels, frozen tissue samples of 17 ccRCCs and
matched non-tumorous tissue were used. The patholog-
ical parameters of the ccRCCs are presented together
with the VHL mutations in Supplementary Table 1.
A previously described tissue microarray (TMA) was
used [21] to determine PTPRJ mRNA expression in
ccRCCs, pRCCs, and normal kidney samples. This
study was approved by the Local Ethics Commission
(reference number StV. 38-2005). All tissue specimens
were supplied by the Tissue Biobank of the University
Hospital Zurich.
mRNA quantification
Quantitative analysis of PTPRJ mRNA expression
was performed by qRT-PCR using 17 ccRCCs with
known VHL mutation status. Normal matched tissue
was available for each tumour and used as a con-
trol. Total RNA was isolated using the RNeasy Mini
Kit (Qiagen, Hilden, Germany) and quantified using
the Nanodrop spectrometer. Total RNA (0.2–1 µg)
was reverse-transcribed using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Fos-
ter City, CA, USA). The expression of the mRNAs of
PTPRJ , HIF-1α, HIF-2α, and GLUT-1 was quantified
using the following TaqMan gene expression assays:
Hs00174561_m1 (PTPRJ ), Hs00936376_m1 (HIF-
1α), Hs01026146_m1 (HIF-2α), and Hs00197884_m1
(GLUT-1 ). The expression assays were designed by
Applied Biosystems and analysed using the 7900 Fast
Real-Time PCR System (Applied Biosystems). The
data were quantified with the comparative Ct method
for relative gene expression and normalized using PPIA
(expression assay Hs99999904_m1) [22].
RNA in situ hybridization (RISH)
PTPRJ mRNA expression was analysed on a TMA
by non-radioactive in situ hybridization adapted from
a previously published protocol [23]. Briefly, total
mRNA was extracted from HeLa cells and the fol-
lowing primers containing the T7 polymerase bind-
ing site (5’-TAATACGACTCACTATAGGGAGAG-3’)
were chosen to amplify two parts of the PTPRJ
mRNA: 5’-GTGAAAGCTCTGGAGCCAAC-3’ and
5’-ACTCCTCATGGCTTCCAATG-3’ spanning exons
3–5 and 5’-GAGATCGGCTTAGCATGGAG-3’ and
5’-TATAAGGTGCCCGGAATCAG-3’ spanning exons
8 and 9. Digoxigenin (DIG)-labelled antisense and
sense riboprobes were transcribed in vitro with T7
RNA polymerase in the presence of digoxigenin-
UTP (Roche Diagnostics, Rotkreuz, Switzerland). For
the hybridization procedure, 1–2 µl of DIG-labelled
sense and antisense probes (about 100–200 ng) was
added to the hybridization mix and denatured at 85◦C
for 5 min. Two-micrometre-thick TMA sections were
incubated at 60◦C overnight. Detection of probe-
target hybrids was performed with NBT/BCIP substrate
(Roche Applied Science). The intensity of the staining
for PTPRJ mRNA expression was classified as fol-
lows: 0 = negative staining; + = 1 reduced staining; and
+2 = strong staining. The intensity of staining detected
in normal proximal tubules was considered as a refer-
ence for strong staining.
Mutation analysis of PTPRJ and VHL
For the mutation analysis of PTPRJ , genomic DNA
was extracted from 32 formalin-fixed and paraffin-
embedded ccRCCs which were also on the large
TMA. Five normal matched tissues were included in
the analysis. The mutation analysis of PTPRJ and
VHL was performed as previously described [16,24].
Mutations were confirmed with at least one separate
PCR and sequence analysis.
Cell lines
The ccRCC cell lines 786-O and RCC4 (transfected
with empty vector), 786-O VHL and RCC4 VHL
(stably expressing pVHL), RCC4 Y98H and RCC4
Y98N (stably expressing the type 2A and type 2B
pVHL mutants Y98H and Y98N, respectively) and
the human renal proximal tubular epithelial cell line
HK2 were used in this study. All cell lines were
grown under conditions recommended by ATCC and
authenticated by short tandem repeat profiling by
Identicell (Department of Molecular Medicine, Aarhus
University, Hospital Skejby, Aarhus, Denmark).
Western blotting and antibodies
Total cell lysates were prepared with RIPA buffer
(Sigma-Aldrich Corp, St Louis, MO, USA) supple-
mented with protease inhibitors (Complete Protease
Inhibitor Cocktail; Roche, Basel, Switzerland). For cell
and tissue fractioning, a Nuclear Extraction Kit (Active
Motif, Carlsbad, CA, USA) and the TissueLyser (Qia-
gen, Hilden, Germany) were used, respectively. West-
ern blot was performed as previously described [6]. The
primary antibodies used were anti-pVHL (diluted 1 :
500; provided by Wilhelm Krek, ETH Zurich, Switzer-
land), anti-HIF-1α (1 : 1000; Cell Signalling, Dan-
vers, MA, USA), anti-HIF-2α (1 : 200; NB 100-122;
Novus Biologicals, Littleton, CO, USA), anti-β-actin (1
: 1000; Chemicon International, Temecula, CA, USA);
anti-PTPRJ (cell line extracts) (1 : 200; H300 sc-22749;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), and
anti-PTPRJ (cell line and tissue extracts) (1 : 500;
Proteintech, Chicago, IL, USA). Secondary antibod-
ies were HRP-conjugated anti-mouse (1 : 2000; ab672;
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Abcam Plc, Cambridge, UK) and HRP-conjugated anti-
rabbit (1 : 2000; Millipore, Billerica, MA, USA). The
protein–antibody complexes were detected by using
ECL (Amersham, Little Chalfont, Buckinghamshire,
UK). Band intensities of PTPRJ and β-actin from west-
ern blots were measured using ImageJ software.
Transient transfections
For RNA interference experiments, RCC4, 786-O,
and HK2 cells were transfected with 5 nM siRNA
oligonucleotides using HiPerfect transfection reagent
(Qiagen). The siRNA sequences (Qiagen; Life Tech-
nologies, Carlsbad, CA, USA) are listed in Supple-
mentary Table 2. AllStars negative controls (Qia-
gen) were used as negative controls. To study the
effects of PTPRJ overexpression in RCC4 cells, the
pQE-TriSystem-6 vector (Qiagen) containing the ORF
of the PTPRJ gene (Entrez Gene: 5795; Ensembl:
ENSG00000149177; UniProtKB: Q12913) was used.
The pQE-TriSystem-6 served as a control (empty vec-
tor). Cells were grown for 24 h in a six-well format and
then transiently transfected with the expression vec-
tor. Cells were harvested after 96 h to evaluate PTPRJ
expression levels by qRT-PCR and western blot.
Luciferase gene reporter assay
Luciferase gene expression assays were performed
as previously described [6]. The nucleotides
between −2682 and +515 were defined as the
putative promoter region of PTPRJ (Chr 11p11.2;
47,971,665:48,222,839, positive strand, NCBI) consid-
ering the A(TG) translation site as +1 reference. The
promoter region was synthesized from GenScript (Pis-
cataway, NJ, USA) and cloned into firefly luciferase
reporter plasmid pGL4.10 (Promega, Madison, WI,
USA). pGL4.10P2P vector containing wild-type P2P
hypoxia response elements (HREs) of the human
PHD2 promoter were provided by Roland Wenger
(University of Zurich, Switzerland) and was used as a
positive control as previously described [6,25].
For transcriptional transactivation experiments, 786-
O cells were transfected with siRNA (HIF-2α #1 or
siScr) and grown in a 24-well format. After 48 h, the
cells were transfected with 1 µg of luciferase reporter
plasmid and 200 ng of pGL4.74 renilla luciferase
reporter plasmid (Promega) using FuGene 6 reagent
(Roche Diagnostics). Luciferase activity was measured
24 h later after cell lysis using the Dual-Luciferase
Reporter Assay System (Promega). Relative luciferase
units were determined according to the manufacturer’s
instructions (Promega) to generate the ratio of the
values obtained from siHIF-2α and siSc treatments.
MTT proliferation assay
RCC4 cells were grown in a six-well format for 24 h
and transfected with the expression or control vector.
MTT proliferation assay (Cell Proliferation Kit I MTT,
Roche Diagnostics) was performed according to the
manufacturer’s protocol. Briefly, transfected cells were
plated in a 96-well plate. After the incubation period,
10 µl of the MTT labelling reagent (final concentration
0.5 mg/ml) was added to each well and cells were
incubated for 4 h. Subsequently, 100 µl of the solu-
bilization solution was added to the wells and cells
were incubated overnight at 37◦C. The solubilized for-
mazan product was quantified using an ELISA reader
(Infinite F200 PRO, Tecan Group Ltd., Ma¨nnedorf,
Switzerland) at wavelength 570 nm. The analysis of
cell proliferation was performed after 96, 120, 144,
and 168 h.
Statistical analysis
Analysis between groups was carried out with two-way
ANOVA and post-hoc Bonferroni multiple comparison
(GraphPad Prism 5). Contingency table analysis and
Pearson’s chi-squared tests were calculated using the
SPSS 17.0 statistical software package. Survival curves
were estimated with the Kaplan–Meier method and
the log-rank test. p values ≤ 0.05 were considered
statistically significant.
Results
Direct correlation of PTPRJ and pVHL expression in
RCC cell lines
Previous mass spectrometry experiments performed
with pVHL-deficient and pVHL-re-expressing RCC
cell lines identified PTPRJ positively linked to pVHL
expression [8]. To confirm that PTPRJ is influ-
enced by the VHL–HIF axis, we used the pVHL-
deficient renal cancer cell lines 786-O and RCC4 and
their corresponding stable pVHL transfectants. Com-
pared with the corresponding pVHL-negative cell lines,
both PTPRJ mRNA (Figure 1A) and protein levels
(Figures 1B and 1C) were increased in the presence of
pVHL.
PTPRJ mRNA expression is decreased in ccRCC
tissue
To quantitatively evaluate PTPRJ mRNA expression
in human RCC samples, we performed qRT-PCR
with 17 ccRCCs and normal matched tissues. PTPRJ
expression was reduced in 15 of 17 ccRCCs (88%)
(Figure 1D) compared with normal renal tissues. Strong
PTPRJ expression was seen in one VHL wild-type
tumour and in one ccRCC with a missense mutation
that causes an amino acid exchange at codon 88
(Figure 1D and Supplementary Table 1). Western
blot analysis with three matched normal/tumour pairs
demonstrated a direct correlation between mRNA and
protein expression of PTPRJ (Figure 1E).
As commercially available PTPRJ antibodies were
not specific in formalin-fixed and paraffin-embedded
tissues, the expression of PTPRJ was analysed by
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Figure 1. Positive correlation between PTPRJ and pVHL expression. (A) PTPRJ mRNA levels measured by qRT-PCR (three replicas ± SD)
in pVHL-negative RCC cell lines and their stable VHL transfectants (increase 1.5- to 1.9-fold). (B) Western blot showing PTPRJ protein
expression in pVHL-negative ccRCC cells and their stable VHL transfectants (loading control: β-actin). (C) Elevated PTPRJ expression in
pVHL expressing 786-O (normalized mean 1.73± 0.42 SD, n = 5, p = 0.026) and RCC4 cells (1.51± 0.64, n = 4, p = ns.). (D) Normalized
PTPRJ mRNA levels measured by qRT-PCR in 17 ccRCCs and their normal matched tissues (three replicas ± SD). The VHL mutation status
in the tumours is indicated (wt =wild type; ms =missense; del fs = deletion leading to frameshift; del ins = deletion and insertion; del X =
deletion leading to a stop codon). (E) Western blot showing PTPRJ protein expression in three ccRCC tissues and matched normal tissues
(loading control: β-actin). Significant differences (p < 0.05) are indicated by asterisks.
RNA in situ hybridization (RISH). The specificity of
DIG-labelled RNA probes for PTPRJ was confirmed
by northern blot analysis using total RNA from HeLa
cells (positive control). The antisense probes bound
a 7.8 kb band corresponding to the PTPRJ transcript
(data not shown).
PTPRJ RISH analysis on a TMA showed strong
positivity in the proximal tubular cells of all analysed
normal kidney tissue samples (Figure 2), whereas
in 198 of 232 (85%) analysable ccRCCs, but in
only 5 of 41 (12%) pRCCs, PTPRJ expression was
reduced (p< 0.001). ccRCC patients with no or low
PTPRJ mRNA expression showed a worse prognosis
than those with a normal expression status (p = 0.05)
(Figure 3). No associations were seen between PTPRJ
expression and tumour stage and grade. The highly
significant difference between the survival curves of
patients with organ-confined and locally advanced
tumours confirmed the validity of the clinical data
(Supplementary Figure 2).
Mutation analysis of PTPRJ in ccRCC
Twenty-two PTPRJ -negative and ten weakly express-
ing ccRCC samples included in the TMA were selected
for mutation analysis of exons 5, 6, 7, and 13 of
PTPRJ . So far, all cancer-related amino acid substi-
tutions have been identified in these four exons, which
code the extracellular portion responsible for interac-
tions with ligands or other proteins [16]. Five normal
matched tissues were also included in this analysis.
We found two conservative (E206E and T233T) and
three non-conservative (Q276P, R326Q, and E872D)
polymorphisms which have been previously reported
[UniprotKB/Swiss-Prot, Q12913 (PTPRJ_HUMAN)].
There were no mutations affecting the reading frame
of PTPRJ .
PTPRJ expression is HIF-2α-dependent
To determine the influence of the pVHL–HIF axis
on PTPRJ expression, we used different pVHL-
expressing and non-expressing RCC cell lines. In
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Figure 2. PTPRJ RISH on a TMA with examples of negative, reduced, and strong PTPRJ mRNA expression in ccRCC and normal kidney.
Figure 3. Kaplan–Meier plot of the overall survival of ccRCC
patients defined by PTPRJ mRNA expression. Survival data were
not available from 18 patients. PTPRJ expression was defined as
reduced if the mRNA staining in a tumour was unequivocally
weaker than that seen in normal kidney.
RCC4 cells expressing the pVHL mutant Y98N, which
fail to degrade HIF-α [26], PTPRJ mRNA expression
was comparable to pVHL-deficient RCC4. In contrast,
in RCC4 cells expressing the pVHL mutant Y98H,
which has only a slight defect in ubiquitination of
HIF-α [26], the PTPRJ mRNA level was increased
and similar to the RCC4 VHL cell line (Figure 4A).
An opposite effect was observed with GLUT1 mRNA,
whose expression increased in the presence of HIF-α
(Figure 4B).
Next, we silenced HIF-1α and HIF-2α by siRNA
in the pVHL-deficient RCC4 cell line to deter-
mine whether the two HIF-α isoforms were able to
down-regulate PTPRJ mRNA expression. Efficient
knockdown of HIF-1α and HIF-2α was confirmed by
qRT-PCR and western blot analysis (Figures 4C–4G).
In RCC4, silencing of HIF-1α had positive effects on
PTPRJ mRNA expression after 48 h (Figure 5A). In
contrast, silencing of HIF-2α produced an increase of
PTPRJ mRNA expression after just 24 h and reached
a two-fold up-regulation after 48 h (Figure 5B).
We also silenced HIF-2α by siRNA in the pVHL
and HIF-1α-null 786-O cell line. After 48 h, we
obtained an increase of PTPRJ mRNA expression
which was comparable to that observed in 786-O
VHL (Figure 5D). Efficient knockdown of HIF-2α
was confirmed by analysing the level of GLUT-1
mRNA (Figure 5F). Western blot analysis confirmed
a strong increase of PTPRJ protein expression in both
HIF-2α silenced ccRCC cell lines (Figures 5C and
5E). Similar results were obtained with two additional
HIF-2α siRNAs excluding possible off target effects
(Supplementary Figures 1A–1C).
Hypoxia response elements in the promoter region
influence PTPRJ expression
The putative promoter region of PTPRJ contains five
HREs and three reverse HREs (Supplementary Table 3
and Figure 6A). To study the influence of the HREs
on PTPRJ expression, a luciferase reporter plasmid
pGL4.10 construct containing 3.2 kb of the PTPRJ
promoter was generated (Figure 6A). By silencing HIF-
2α in 786-O cells (Figure 6B), the reporter activity of
the vector increased significantly compared with those
of the empty plasmid and the P2P promoter construct
(Figure 6C). These results show that HIF-2α negatively
regulates PTPRJ via the identified putative HREs in its
promoter region.
PTPRJ regulates cell proliferation
RCC4 cells transfected with the Qiagen expression
vector pQE-TriSystem 6 containing the PTPRJ gene
showed increased mRNA and protein expression of
PTPRJ (Figure 6D and 6E). RCC4 cells transfected
with the PTPRJ vector showed a significantly reduced
proliferation rate compared with the control group
(Figure 6F).
We also silenced PTPRJ by siRNA in wild-type
pVHL expressing HK2 to see if PTPRJ down-
regulation leads to increased cell proliferation in the
presence of pVHL. Reduced expression negatively
influenced cell proliferation after 72 h (Supplementary
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Figure 4. (A) PTPRJ mRNA transcription in RCC4 VHL, RCC4 Y98H (HIF-α destabilizing VHL mutation), and RCC4 Y98N (HIF-α non-
destabilizing VHL mutation) cells. (B) GLUT-1 mRNA expression in the same RCC4 cells. (C, D) Knockdown efficiency of siHIF-1α and
siHIF-2α on HIF-1α (C) and HIF-2α (D) mRNA expression after 24 and 48 h in RCC4 cells. (E) Western blot showing down-regulated HIF-1α
and HIF-2α protein expression in RCC4 cells. (F) HIF-2α mRNA expression in siHIF-2α transfected 786-O cells after 24 and 48 h. (G)
Western blot showing down-regulated HIF-2α protein expression (loading control: β-actin). Significant differences (p < 0.05) of PTPRJ,
GLUT-1, HIF-1α, and HIF-2α expression compared with wild-type cell lines are indicated by asterisks.
Figures 3A and 3B) and suggests that loss of PTPRJ
is biologically relevant to promote growth of ccRCC,
independently of the pVHL expression status.
Discussion
We have demonstrated that decreased PTPRJ expres-
sion is characteristic for the vast majority of ccRCCs.
In vitro experiments showed that higher PTPRJ mRNA
and protein expression levels are closely linked to
the presence of functional pVHL. Down-regulation of
PTPRJ is mainly dependent on HIF-2α stabilization
following pVHL loss.
Our TMA analysis showed no or low PTPRJ mRNA
expression in 85% of ccRCCs, whereas in most of
the pRCCs, PTPRJ mRNA levels were comparable to
those in normal tissues. The fact that VHL is mutation-
ally affected in about 70–80% of ccRCCs [1,27,28]
suggests a close relationship between PTPRJ mRNA
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Figure 5. PTPRJ expression depends mainly on HIF-2α. (A) Increase of PTPRJ mRNA expression in RCC4 cells after silencing of HIF-1α and
(B) after silencing of HIF-2α. (C) Western blot showing PTPRJ protein expression in RCC4 cells after silencing of HIF-1α and HIF-2α. (D)
Increase of PTPRJ mRNA levels in 786-O cells after silencing of HIF-2α. (E) PTPRJ protein expression after silencing of HIF-2α. (F) GLUT-1
mRNA expression in HIF-2α silenced 786-O cells. Data represent the mean of two experiments carried out in triplicate ± SD. Significant
differences (p < 0.05) of PTPRJ and GLUT-1 expression compared with wild-type cell lines are indicated by asterisks.
expression and pVHL functional integrity. This is sup-
ported by the observation that PTPRJ expression was
normal in almost 90% of the analysed pRCCs in which
VHL is hardly mutated [29]. This result confirms our
recent proteomics finding of a relationship between
PTPRJ expression and pVHL in human tissue [8]. In
our test set of 17 ccRCCs, reduced PTPRJ mRNA
expression was also seen in two of four tumours with
wild-type VHL. Other mechanisms of VHL inactiva-
tion, such as tumour hypoxia or hypermethylation of
the VHL promoter, which occurs in about half of
VHL wild-type ccRCCs [1,28,30], may explain this
observation.
Here, we identified PTPRJ as a potential target
of HIF-2α. HIF-1α and HIF-2α share high similarity
in their DNA binding and dimerization domains, but
they differ in their transactivation domains [31]. As
a consequence, there are common gene targets, but
also genes that are preferentially regulated by one of
the two isoforms. HIF-1α seems to preferentially drive
the transcription of genes encoding glycolytic enzymes
and pro-apoptotic factors, such as BCL2/adenovirus
E1B-interacting protein 1, NIP3 (BNIP3). In contrast,
HIF-2α induces the expression of pro-survival factors
such as VEGF, TGF-α, and CCND1 [32]. Studies
demonstrated that HIF-α can also down-regulate genes
either by inducing repressors of transcription or by
directly binding to HREs and to reverse HREs. The
latter are present in the antisense strand of the promoter
of HIF target genes. Examples of genes directly down-
regulated by HIF-1α are AFP [33], PPARA [34], and
RECK [35], whereas genes directly or indirectly down-
regulated by HIF-2α have not been described to date.
The analysis of the putative PTPRJ promoter
showed the presence of five putative HREs and three
putative reverse HREs. Since we observed PTPRJ
down-regulation in the presence of HIF-2α, we asked
whether HIF could directly act as a suppressor of
PTPRJ transcription. Using 786-O cells, significant
effects were seen with our luciferase gene reporter
assays, suggesting that the HREs and reverse HREs
identified in the putative PTPRJ promoter region
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Figure 6. PTPRJ promoter activity is HIF-2α-dependent. (A)
Schematic representation of the 3.2 kb PTPRJ promoter with the
location of the five HREs and three reverse HREs. (B) Western
blot showing efficient knockdown of HIF -2α in 786-O cells after
72 h (loading control: β-actin). (C) Luciferase reporter gene
assay with P2P (HIF target) and PTPRJ vector constructs after
transient transfection of siScrambled and siHIF-2α using 786-O
cells. Decrease of P2P and increase of PTPRJ promoter activity after
HIF -2α silencing. (D) PTPRJ mRNA levels measured by qRT-PCR in
RCC4 cells untreated, transfected with scrambled control, and with
PTPRJ expression vector 96 h after transfection. Data represent the
mean of three replicas ± SD. (E) Immunoblot of PTPRJ expression
in RCC4 cells untreated, transfected with scrambled control, and
with PTPRJ expression vector 96 h after transfection. RQ = relative
quantification. (F) Proliferation of RCC4 cells 96, 120, 144, and 168
h after transfection with empty vector (control) or PTPRJ expression
vector (PTPRJ).
are important for suppressing PTPRJ expression
by HIF-2α. It is of note that only two-fold over-
expression of PTPRJ in RCC4 cells was sufficient
to produce a significant inhibitory effect on cell
proliferation. Our result expands the findings of
previous studies that describe anti-proliferative
properties of PTPRJ in non-RCC tumour cell
lines [10,12,14].
To evaluate the presence of mutations of the PTPRJ
gene, we performed a sequence analysis of exons 5, 6,
7, and 13 of PTPRJ in 32 ccRCCs. We found two con-
servative and three non-conservative polymorphisms,
but no mutation predicting severe consequences on
PTPRJ function. Similar frequencies of these poly-
morphisms were found in studies which analysed the
PTPRJ genotype in other tumour types and in other
populations [36–38]. The real influence of these poly-
morphisms on PTPRJ expression and function is still
not fully understood. Our results suggest that in ccRCC
the down-regulation of PTPRJ expression is obviously
Figure 7. Schematic representation of the HIF-α-dependent
regulation of PTPRJ expression in normal kidney and ccRCC.
not caused by mutations but is mainly due to the dereg-
ulation of the pVHL/HIF pathway (Figure 7).
PTPRJ’s inhibitory effect on cell proliferation in
ccRCC, as shown by us, and in other tumour types
[14,39,40], as well as its ability to regulate EGFR phos-
phorylation [17], suggests its important influence on
the activity of EGFR. Although EGFR overexpression
occurs in the majority of ccRCCs and is correlated
with rapid tumour cell proliferation and worse patient
outcome [41,42], anti-EGFR targeted therapies have
shown only low response rates [43,44]. As demon-
strated in non-small cell lung cancer, the success of
such therapies is obviously dependent on EGFR acti-
vating mutations [45], which have not been found in
ccRCC [41]. Antibodies against phosphorylated and
activated EGFR are available but their use for reli-
ably determining its tyrosine kinase activity status
on formalin-fixed, paraffin-embedded tissue in routine
diagnostics is challenging [46]. Despite the low num-
ber of tumours analysed, our western blot data indicate
reduced PTPRJ expression also at the protein level in a
subset of ccRCCs. It is conceivable that EGFR-positive
tumours with strongly reduced PTPRJ may respond
better to inhibitors against EGFR and its downstream
targets, such as PI3K, AKT, and mTOR, than those
showing normal PTPRJ expression. However, addi-
tional experiments using optimized antibodies as well
as appropriate mouse models are needed to character-
ize the biological relevance of PTPRJ down-regulation
by the pVHL–HIF axis and its clinical applicability for
this tumour subtype.
In summary, we have shown that down-regulation
of PTPRJ is a characteristic feature in ccRCC that is
closely linked to the loss of pVHL function and the
activation of HIF. Molecular studies of low abundance
genes, such as PTPRJ , are a big challenge in cancer
research as they are more sophisticated compared to
investigations of those genes that become clearly up-
or down-regulated in tumours. They are, nevertheless,
necessary to better understand the complex genetic
network of cancer.
Copyright  2012 Pathological Society of Great Britain and Ireland. J Pathol 2013; 229: 525–534
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
PTPRJ in clear cell renal cell carcinoma 533
Acknowledgments
We thank Roger Santimaria and Martina Storz for
excellent technical assistance. We thank Claudio
Thoma (ETH Zurich, Switzerland) and Rudolf
Wu¨thrich (University Hospital of Zurich, Switzerland)
for the cell lines and Daniel Stiehl (University of
Zurich, Switzerland) for the luciferase vectors. This
study was supported by the Swiss National Science
Foundation (3238BO-103145; to HM) and the Zurich
Cancer League (to HM).
Author contribution statement
SC and MRu conceived and carried out experiments
and generated the figures. MRe conceived experiments
and interpreted data. LM, SB-S, and AvT carried
out experiments. WK designed the study. PS and
HM designed the study, analysed data, and wrote the
manuscript. HM reviewed the tumours. All authors had
final approval of the submitted and published versions.
References
1. Banks RE, Tirukonda P, Taylor C, et al . Genetic and epigenetic
analysis of von Hippel–Lindau (VHL) gene alterations and rela-
tionship with clinical variables in sporadic renal cancer. Cancer
Res 2006; 66: 2000–2011.
2. Frew IJ, Krek W. Multitasking by pVHL in tumour suppression.
Curr Opin Cell Biol 2007; 19: 685–690.
3. Gossage L, Eisen T. Alterations in VHL as potential biomarkers in
renal-cell carcinoma. Nature Rev Clin Oncol 2010; 7: 277–288.
4. Bluyssen HA, Lolkema MP, van Beest M, et al . Fibronectin is a
hypoxia-independent target of the tumor suppressor VHL. FEBS
Lett 2004; 556: 137–142.
5. Esteban MA, Tran MG, Harten SK, et al . Regulation of E-cadherin
expression by VHL and hypoxia-inducible factor. Cancer Res 2006;
66: 3567–3575.
6. Luu VD, Boysen G, Struckmann K, et al . Loss of VHL and hypoxia
provokes PAX2 up-regulation in clear cell renal cell carcinoma. Clin
Cancer Res 2009; 15: 3297–3304.
7. Roe JS, Kim H, Lee SM, et al . p53 stabilization and transactivation
by a von Hippel–Lindau protein. Mol Cell 2006; 22: 395–405.
8. Boysen G, Bausch-Fluck D, Thoma CR, et al . Identification and
functional characterization of pVHL-dependent cell surface proteins
in renal cell carcinoma. Neoplasia 2012; 14: 535–546.
9. Honda H, Inazawa J, Nishida J, et al . Molecular cloning, character-
ization, and chromosomal localization of a novel protein-tyrosine
phosphatase, HPTP eta. Blood 1994; 84: 4186–4194.
10. Balavenkatraman KK, Jandt E, Friedrich K, et al . DEP-1 protein
tyrosine phosphatase inhibits proliferation and migration of colon
carcinoma cells and is upregulated by protective nutrients. Onco-
gene 2006; 25: 6319–6324.
11. Jandt E, Denner K, Kovalenko M, et al . The protein-tyrosine phos-
phatase DEP-1 modulates growth factor-stimulated cell migration
and cell–matrix adhesion. Oncogene 2003; 22: 4175–4185.
12. Kellie S, Craggs G, Bird IN, et al . The tyrosine phosphatase DEP-
1 induces cytoskeletal rearrangements, aberrant cell–substratum
interactions and a reduction in cell proliferation. J Cell Sci 2004;
117: 609–618.
13. Trapasso F, Iuliano R, Boccia A, et al . Rat protein tyrosine
phosphatase eta suppresses the neoplastic phenotype of retrovirally
transformed thyroid cells through the stabilization of p27(Kip1).
Mol Cell Biol 2000; 20: 9236–9246.
14. Trapasso F, Yendamuri S, Dumon KR, et al . Restoration of
receptor-type protein tyrosine phosphatase eta function inhibits
human pancreatic carcinoma cell growth in vitro and in vivo.
Carcinogenesis 2004; 25: 2107–2114.
15. Ruivenkamp C, Hermsen M, Postma C, et al . LOH of PTPRJ occurs
early in colorectal cancer and is associated with chromosomal loss
of 18q12–21. Oncogene 2003; 22: 3472–3474.
16. Ruivenkamp CA, van Wezel T, Zanon C, et al . Ptprj is a
candidate for the mouse colon-cancer susceptibility locus Scc1 and
is frequently deleted in human cancers. Nature Genet 2002; 31:
295–300.
17. Tarcic G, Boguslavsky SK, Wakim J, et al . An unbiased screen
identifies DEP-1 tumor suppressor as a phosphatase controlling
EGFR endocytosis. Curr Biol 2009; 19: 1788–1798.
18. Kovalenko M, Denner K, Sandstrom J, et al . Site-selective dephos-
phorylation of the platelet-derived growth factor beta-receptor by
the receptor-like protein-tyrosine phosphatase DEP-1. J Biol Chem
2000; 275: 16219–16226.
19. Grazia Lampugnani M, Zanetti A, Corada M, et al . Contact inhi-
bition of VEGF-induced proliferation requires vascular endothelial
cadherin, beta-catenin, and the phosphatase DEP-1/CD148. J Cell
Biol 2003; 161: 793–804.
20. Palka HL, Park M, Tonks NK. Hepatocyte growth factor receptor
tyrosine kinase met is a substrate of the receptor protein-tyrosine
phosphatase DEP-1. J Biol Chem 2003; 278: 5728–5735.
21. Mertz KD, Demichelis F, Kim R, et al . Automated immunofluores-
cence analysis defines microvessel area as a prognostic parameter
in clear cell renal cell cancer. Hum Pathol 2007; 38: 1454–1462.
22. Jung M, Ramankulov A, Roigas J, et al . In search of suitable
reference genes for gene expression studies of human renal cell
carcinoma by real-time PCR. BMC Mol Biol 2007; 8: 47.
23. Theurillat JP, Zurrer-Hardi U, Varga Z, et al . Distinct expression
patterns of the immunogenic differentiation antigen NY-BR-1 in
normal breast, testis and their malignant counterparts. Int J Cancer
2008; 122: 1585–1591.
24. Schraml P, Frew IJ, Thoma CR, et al . Sporadic clear cell renal cell
carcinoma but not the papillary type is characterized by severely
reduced frequency of primary cilia. Mod Pathol 2009; 22: 31–36.
25. Metzen E, Stiehl DP, Doege K, et al . Regulation of the prolyl
hydroxylase domain protein 2 (phd2/egln-1 ) gene: identification of
a functional hypoxia-responsive element. Biochem J 2005; 387:
711–717.
26. Thoma CR, Frew IJ, Hoerner CR, et al . pVHL and GSK3beta are
components of a primary cilium-maintenance signalling network.
Nature Cell Biol 2007; 9: 588–595.
27. Rechsteiner MP, von Teichman A, Nowicka A, et al . VHL gene
mutations and their effects on hypoxia inducible factor HIFα:
identification of potential driver and passenger mutations. Cancer
Res 2011; 71: 5500–5511.
28. Nickerson ML, Jaeger E, Shi Y, et al . Improved identification of
von Hippel–Lindau gene alterations in clear cell renal tumors. Clin
Cancer Res 2008; 14: 4726–4734.
29. Brauch H, Weirich G, Brieger J, et al . VHL alterations in human
clear cell renal cell carcinoma: association with advanced tumor
stage and a novel hot spot mutation. Cancer Res 2000; 60:
1942–1948.
30. Herman JG, Latif F, Weng Y, et al . Silencing of the VHL tumor-
suppressor gene by DNA methylation in renal carcinoma. Proc Natl
Acad Sci U S A 1994; 91: 9700–9704.
Copyright  2012 Pathological Society of Great Britain and Ireland. J Pathol 2013; 229: 525–534
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
534 S Casagrande et al
31. Hu CJ, Wang LY, Chodosh LA, et al . Differential roles of
hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene
regulation. Mol Cell Biol 2003; 23: 9361–9374.
32. Raval RR, Lau KW, Tran MG, et al . Contrasting proper-
ties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von
Hippel–Lindau-associated renal cell carcinoma. Mol Cell Biol
2005; 25: 5675–5686.
33. Mazure NM, Chauvet C, Bois-Joyeux B, et al . Repression of
α-fetoprotein gene expression under hypoxic conditions in human
hepatoma cells: characterization of a negative hypoxia response
element that mediates opposite effects of hypoxia inducible factor-1
and c-Myc. Cancer Res 2002; 62: 1158–1165.
34. Narravula S, Colgan SP. Hypoxia-inducible factor 1-mediated inhi-
bition of peroxisome proliferator-activated receptor alpha expres-
sion during hypoxia. J Immunol 2001; 166: 7543–7548.
35. Lee KJ, Lee KY, Lee YM. Downregulation of a tumor suppressor
RECK by hypoxia through recruitment of HDAC1 and HIF-1α to
reverse HRE site in the promoter. Biochim Biophys Acta 2010;
1803: 608–616.
36. Iuliano R, Le Pera I, Cristofaro C, et al . The tyrosine phosphatase
PTPRJ/DEP-1 genotype affects thyroid carcinogenesis. Oncogene
2004; 23: 8432–8438.
37. Iuliano R, Palmieri D, He H, et al . Role of PTPRJ genotype in
papillary thyroid carcinoma risk. Endocr Relat Cancer 2010; 17:
1001–1006.
38. Mita Y, Yasuda Y, Sakai A, et al . Missense polymorphisms of
PTPRJ and PTPN13 genes affect susceptibility to a variety of
human cancers. J Cancer Res Clin Oncol 2010; 136: 249–259.
39. Iuliano R, Trapasso F, Le Pera I, et al . An adenovirus carrying the
rat protein tyrosine phosphatase eta suppresses the growth of human
thyroid carcinoma cell lines in vitro and in vivo. Cancer Res 2003;
63: 882–886.
40. Keane MM, Lowrey GA, Ettenberg SA, et al . The protein tyrosine
phosphatase DEP-1 is induced during differentiation and inhibits
growth of breast cancer cells. Cancer Res 1996; 56: 4236–4243.
41. Minner S, Rump D, Tennstedt P, et al . Epidermal growth factor
receptor protein expression and genomic alterations in renal cell
carcinoma. Cancer 2012; 118: 1268–1275.
42. Moch H, Sauter G, Buchholz N, et al . Epidermal growth factor
receptor expression is associated with rapid tumor cell proliferation
in renal cell carcinoma. Hum Pathol 1997; 28: 1255–1259.
43. Drucker B, Bacik J, Ginsberg M, et al . Phase II trial of ZD1839
(IRESSA) in patients with advanced renal cell carcinoma. Invest
New Drugs 2003; 21: 341–345.
44. Rowinsky EK, Schwartz GH, Gollob JA, et al . Safety, pharma-
cokinetics, and activity of ABX-EGF, a fully human anti-epidermal
growth factor receptor monoclonal antibody in patients with
metastatic renal cell cancer. J Clin Oncol 2004; 22: 3003–3015.
45. Lynch TJ, Bell DW, Sordella R, et al . Activating mutations in
the epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:
2129–2139.
46. Becker KF, Mack H, Schott C, et al . Extraction of phosphorylated
proteins from formalin-fixed cancer cells and tissues. Open Pathol
J 2008; 2: 46–52.
Copyright  2012 Pathological Society of Great Britain and Ireland. J Pathol 2013; 229: 525–534










































































in  the  evolution of papillary  renal  cell neoplasia: a  fluorescent  in  situ hybridization 
study. Mod Pathol, 2003. 16(10): p. 1053‐9. 















41.  Eichelberg,  C.,  et  al.,  Diagnostic  and  prognostic  molecular  markers  for  renal  cell 
carcinoma: a critical appraisal of the current state of research and clinical applicability. 
Eur Urol, 2009. 55(4): p. 851‐63. 






























54.  Maxwell, P.H., et  al.,  The  tumour  suppressor protein VHL  targets hypoxia‐inducible 
factors for oxygen‐dependent proteolysis. Nature, 1999. 399(6733): p. 271‐5. 
55.  Hergovich,  A.,  et  al.,  Regulation  of microtubule  stability  by  the  von  Hippel‐Lindau 
tumour suppressor protein pVHL. Nat Cell Biol, 2003. 5(1): p. 64‐70. 









































71.  Shen, C., et al., Genetic and  functional studies  implicate HIF1alpha as a 14q kidney 
cancer suppressor gene. Cancer Discov, 2011. 1(3): p. 222‐35. 
72.  Koh, M.Y., et al., The hypoxia‐associated factor switches cells from HIF‐1alpha‐ to HIF‐






75.  Xu,  J., et  al.,  Epigenetic  regulation of HIF‐1alpha  in  renal  cancer  cells  involves HIF‐
1alpha/2alpha binding to a reverse hypoxia‐response element. Oncogene, 2012. 31(8): 
p. 1065‐72. 






78.  Kaelin, W.G.,  Jr., The von Hippel‐Lindau  tumour suppressor protein: O2 sensing and 
cancer. Nat Rev Cancer, 2008. 8(11): p. 865‐73. 
79.  Lau,  K.W.,  et  al.,  Target  gene  selectivity  of  hypoxia‐inducible  factor‐alpha  in  renal 
cancer cells is conveyed by post‐DNA‐binding mechanisms. Br J Cancer, 2007. 96(8): p. 
1284‐92. 















87.  Li, L., et al., DNA methylation  in peripheral blood: a potential biomarker  for cancer 
molecular epidemiology. J Epidemiol, 2012. 22(5): p. 384‐94. 
88.  Ganti,  S.  and  R.H.  Weiss,  Urine  metabolomics  for  kidney  cancer  detection  and 
biomarker discovery. Urol Oncol, 2011. 29(5): p. 551‐7. 

















96.  Michigan,  A.,  T.V.  Johnson,  and  V.A. Master,  Preoperative  C‐reactive  protein  level 
adjusted  for comorbidities and  lifestyle  factors predicts overall mortality  in  localized 
renal cell carcinoma. Mol Diagn Ther, 2011. 15(4): p. 229‐34. 





99.  Byun,  S.S.,  et  al.,  Expression  of  survivin  in  renal  cell  carcinomas:  association with 
pathologic features and clinical outcome. Urology, 2007. 69(1): p. 34‐7. 
100.  Zigeuner, R.,  et  al., Biologic  significance  of  fascin  expression  in  clear  cell  renal  cell 
carcinoma: systematic analysis of primary and metastatic tumor tissues using a tissue 
microarray technique. Urology, 2006. 68(3): p. 518‐22. 
101.  Gibney, G.T., et al., c‐Met  is a prognostic marker and potential therapeutic target  in 
clear cell renal cell carcinoma. Ann Oncol, 2013. 24(2): p. 343‐9. 
































the  nerve  growth  factor  receptor  family,  gives  rise  to  a  soluble  form  by  protein 
processing that does not involve receptor endocytosis. Eur J Immunol, 1992. 22(2): p. 
447‐55. 
116.  Lens,  S.M.,  et  al.,  Control  of  lymphocyte  function  through  CD27‐CD70  interactions. 
Semin Immunol, 1998. 10(6): p. 491‐9. 
117.  Nolte, M.A., et al., Timing and tuning of CD27‐CD70 interactions: the impact of signal 
strength  in setting  the balance between adaptive  responses and  immunopathology. 
Immunol Rev, 2009. 229(1): p. 216‐31. 


























127.  Held‐Feindt,  J. and R. Mentlein, CD70/CD27  ligand, a member of  the TNF  family,  is 
expressed in human brain tumors. Int J Cancer, 2002. 98(3): p. 352‐6. 
128.  Agathanggelou, A., et al., Expression of immune regulatory molecules in Epstein‐Barr 
virus‐associated  nasopharyngeal  carcinomas  with  prominent  lymphoid  stroma. 





of  tumor‐reactive  lymphocytes  in  clear  cell  renal  cell  carcinoma. Cancer Res, 2012. 
72(23): p. 6119‐29. 











pyrrolobenzodiazepine  drug  with  site‐specific  conjugation  technology.  Bioconjug 
Chem, 2013. 24(7): p. 1256‐63. 
136.  Tannir, N.M., et al., Phase  I dose‐escalation study of SGN‐75  in patients with CD70‐






138.  Lu, Q., A. Wu, and B.C. Richardson, Demethylation of  the  same promoter  sequence 
increases CD70 expression in lupus T cells and T cells treated with lupus‐inducing drugs. 
J Immunol, 2005. 174(10): p. 6212‐9. 
139.  Ma,  L., et al.,  Increased expressions of DNA methyltransferases  contribute  to CD70 

































152.  Worth, C.L., R.  Preissner,  and  T.L.  Blundell,  SDM‐‐a  server  for  predicting  effects  of 
mutations on protein stability and malfunction. Nucleic Acids Res, 2011. 39(Web Server 
issue): p. W215‐22. 
153.  Russell,  R.C.  and M. Ohh,  The  role  of  VHL  in  the  regulation  of  E‐cadherin:  a  new 
connection in an old pathway. Cell Cycle, 2007. 6(1): p. 56‐9. 












159.  Aulwurm,  S.,  et  al.,  Immune  stimulatory  effects  of  CD70  override  CD70‐mediated 
immune  cell apoptosis  in  rodent glioma models and  confer  long‐lasting antiglioma 
immunity in vivo. Int J Cancer, 2006. 118(7): p. 1728‐35. 


























172.  Hedrich,  C.M.  and  T.  Rauen,  Epigenetic  patterns  in  systemic  sclerosis  and  their 
contribution to attenuated CD70 signaling cascades. Clin Immunol, 2012. 143(1): p. 1‐
3. 












cells breaks CD8+ T  cell  tolerance and permits effective  immunity.  Immunity, 2008. 
29(6): p. 934‐46. 
178.  Roberts, D.J., et al., Control of established melanoma by CD27 stimulation is associated 
with  enhanced  effector  function  and  persistence,  and  reduced  PD‐1  expression  of 
tumor infiltrating CD8(+) T cells. J Immunother, 2010. 33(8): p. 769‐79. 
179.  Arens,  R.,  et  al.,  Tumor  rejection  induced  by  CD70‐mediated  quantitative  and 
qualitative effects on effector CD8+ T cell formation. J Exp Med, 2004. 199(11): p. 1595‐
605. 
180.  Riether,  C.,  C.  Schurch,  and  A.F.  Ochsenbein, Modulating  CD27  signaling  to  treat 
cancer. Oncoimmunology, 2012. 1(9): p. 1604‐1606. 
181.  Ciccarelli,  B.T.,  et  al.,  Soluble  CD27  is  a  faithful marker  of  disease  burden  and  is 
unaffected  by  the  rituximab‐induced  IgM  flare,  as  well  as  by  plasmapheresis,  in 















aberrant cell‐substratum  interactions and a  reduction  in cell proliferation.  J Cell Sci, 
2004. 117(Pt 4): p. 609‐18. 
187.  Trapasso,  F.,  et  al.,  Restoration  of  receptor‐type  protein  tyrosine  phosphatase  eta 
function  inhibits  human  pancreatic  carcinoma  cell  growth  in  vitro  and  in  vivo. 
Carcinogenesis, 2004. 25(11): p. 2107‐14. 
188.  Keane,  M.M.,  et  al.,  The  protein  tyrosine  phosphatase  DEP‐1  is  induced  during 
differentiation and inhibits growth of breast cancer cells. Cancer Res, 1996. 56(18): p. 
4236‐43. 






192.  Turley, R.S., et al., The  type  III  transforming growth  factor‐beta  receptor as a novel 
tumor suppressor gene in prostate cancer. Cancer Res, 2007. 67(3): p. 1090‐8. 
193.  Gordon, K.J., et al., Loss of type III transforming growth factor beta receptor expression 















198.  Lopez‐Casillas,  F.,  et  al.,  Structure  and  expression  of  the  membrane  proteoglycan 
betaglycan, a component of the TGF‐beta receptor system. Cell, 1991. 67(4): p. 785‐95. 
199.  Ingold, B., et al., Renal cell carcinoma marker  reliably discriminates central nervous 





201.  Dahinden,  C.,  et  al.,  Mining  tissue  microarray  data  to  uncover  combinations  of 
biomarker expression patterns that improve intermediate staging and grading of clear 
cell renal cell cancer. Clin Cancer Res, 2010. 16(1): p. 88‐98. 






















































































































I  also  appreciate  the  collaborations  with  Prof.  Maries  van  den  Broek  and  Prof.  Arndt 
Hartmann.  
My thanks for technical assistance in the lab go to Christiane Mittmann, Martina Storz, Adriana 
von  Teichmann,  Sonja  Brun‐Schmid, Annette Bohnert,  Peggy  Tzscheetzsch, André  Fitsche, 




Corrò, Magda  Lukamowics‐Rajska, Marion  Bawohl,  Timo  Böge,  Friedericke  Böhm, Monika 
Wolf, Mohsen Malehmir,  Renaud Maire, Maria  Zimmermann‐Dours, Dieter  Zimmermann, 
Ruben Casanova, Elisa Bianchi, Adi Kashyap, Alex Soltermann, Nadja Valtcheva, Christine Fritz, 
Ed Fritz, Qing Zhong and Uli Wagner for creating such a nice working atmosphere. I hope that 
the friendships will last for years to come.  
I also like to thank my dear friend Hella Bolck I have spent a nice time with in Zurich. 
I am very thankful for the loving care of my mum, my dad, my brother and my grandmother 
which well prepared me for my path of life.  
My biggest thank goes to Matze for realizing our dreams.  
